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Abortion bovine genital tract infections and, 218bovine trichomoniasis and, 224brucellosis and, 218equine abortion virus and, 361--363equine arteritis virus and, 363--364*Haemophilus somnus* infection and, 219α~1~-Acid glycoprotein, 644, 646, 647, 648Acquired immunity, *see also* Active immunity; Protective immunity cytokine modulation of, 449--450, 458*Actinobacillus pleuropneumoniae*, 46, 421, 423, 427Active immunity, *see also* Acquired immunity; Protective immunity inhibition of, immunoglobulin G and, 172in poultry, 483pseudorabies vaccines and, 621--622Active substance, new European definition of, 599--600Acute phase protein assays biochemical, 647--648immunochemical, 648--649international reference preparations and, 651--652need for international standardization in, 644--645, 647, 649--650Acute phase proteins, 643--647Adenovirus vector, 151Adhesion molecules, *see also individual molecules* effects of glucocorticoids on, 74leukocyte trafficking and, 65, 68--69lymphocyte trafficking and, 62--63Adjuvants, 4--5; *see also* Freund\'s adjuvant; Mucosal adjuvanticity antigen presenting cells and, 407cholera toxin and, 85--98, 99, 106 B subunit, 106, 110, 111for culture filtrate fraction vaccine, 140cytokines as, 448--449, 450, 457--458, 486--487in DNA immunization, 168, 169in fish immunization, 541for foot-and-mouth disease vaccine, 198heat labile toxin and, 106, 110in helminth vaccines, 246, 247immune stimulating complexes and, 405, 406, 408--409injection site reactions and, 169, 620modulation of immune responses by, 448--449for transmissible gastroenteritis virus vaccines, 440in USDA type I recombinant vaccines, 573virus vectors and, 148--149ADP ribosylation, cholera toxin and, 84, 85, 106Adrenocorticotropic hormone, 63, 70Adverse event report data bias and, 755--757, 769concepts of causality and, 754--755confounding events and, 756--757defining single events in, 769, 771difficulties in interpreting, 749--750, 757--758, 772--773event reporting process and, 753hypothesis testing and, 758, 764--766interval estimation and, 763--764loglinear modeling and, 766--769misused in marketing, 771--772overdispersion and, 760--762, 769probability and, 757, 769quantitative analysis of, 758--769reporting rate *vs.* incidence rate in, 755--756Adverse reactions autoimmunity and, 734causes of, 684--691, 696clinical overview of, 716--717immune-mediated disease, 715overvaccination and, 701--702, 718polyvalent vaccines and, 718--719postmarketing surveillance and, 708--709, 710sources of data on, 704--706types of, 703--704vaccine contamination and, 717--718Advertisements, misuse of adverse event report data in, 771--772*Aeromonas salmonicida*, 525, 547--549; *see also* FurunculosisAerosolization, mink distemper vaccine and, 562Afferent lymph veiled cells, 284--285African cape hunting dogs, 552African horse sickness, 365--366Agammaglobulinemia, 452AgI/II adhesin, 106--108, 109AIDS, *see also* HIV-1 *Bartonella henselae* and, 340infectious disease and, 334--335*Toxoplasma gondii* and, 335, 336*Ailurus fulgens*, 552Akitas, vaccine-associated disease in, 721--723Albumin, acute phase proteins and, 645Aleutian disease parvovirus, 558, 563Allergies, adverse vaccine reactions and, 690, 719Alpha herpesviruses, 361--362, 451Alphavirus, 364Aluminum hydroxide, in helminth vaccines, 246, 247*Amblyomma americanum*, 662American Association of Feline Practitioners, on feline infectious peritonitis vaccination, 355--356American Veterinary Medical Association, 658Aminopeptidases, 245Amyloid A protein, 646Amyloidosis, 646, 722Anamnestic eosinophilia, 391, 400Anamnestic recall response, *see also* Secondary immune response HIV-1 infection and, 127Anaphylaxis, 304, 637, 688--689Animal and Plant Health Inspection Service, 586, 587, 590, 591, 592, 593, 627, 682Animal breeding genetic health enhancement and, 40, 41--49value of acute phase protein assays to, 644Animal growth conjugated linoleic acid and, 56immune-induced wasting and, 53--57Animal health effects of vaccination on, 664--665genetics and, 40--41genetic enhancement of, 39--40, 41--49partnership model for, 667Animal management, occurrence of infectious disease and, 417Animal owners responsibilities of, 6vaccine label information and, 634Animal products, antimicrobial residues and, 664Animals age of, vaccine label statements on, 639--640conjugated linoleic acid and, 56DNA immunization and, 165, 175geriatric, frequency of vaccination and, 725--726, 728immune-induced wasting and, 53--57nonvaccinated, *see* Nonvaccinated animalsyoung, *see* NeonatesAnimal side tests, 210Annual vaccinations, *see also* Revaccination adverse reactions and, 701--702, 718canine vaccines and, 295, 303for dogs, 318vaccine label statements on, 639Anorexia, immune-induced, 55, 56--57Anterior uveitis, 689Anthelmitics, 390Anthrax vaccines, 11--17, 22Antibiotics in aquaculture, 540, 542--543effects on animal performance, 54residues in animal products, 664resistance to, 664Antibodies, *see also* Autoantibodies; Maternal antibodies anti-DNA, 173 antigen recognition and, 182--184in bovine respiratory syncytial virus immunity, 188in deceptive imprinting, 118, 119, 128DNA immunization and, 165, 168--169, 173passive, *see* Passive immunityAntibody-dependent enhancement, 351, 352--353, 354, 355Antibody detection for bovine herpesvirus 1, 205--206for bovine virus diarrhea virus, 209enzyme-linked immunoabsorbent assays and, 372for foot-and-mouth disease, 200in poultry, 488--489Antibody-mediated immune response, *see* Humoral immune responseAntibody-secreting cells in mucosal immune response, 435, 436, 438, 439parasite antigens and, 243--244porcine group A rotaviruses and, 441--442α*1*-Antichymotrypsin, 648Antidistemper vaccines, *see* Canine distemper vaccinesAnti-DNA antibodies, 173Anti-fibronectin antibodies, 738, 742--743, 744, 745Antigastrointestinal peptides, 56--57Antigen(s), *see also* Epitopes; Novel antigens; Protective antigensASC probes and, 243--244 in B cell evolution, 123classes of, 122--123conventional and unconventional, 121effects on DNA immunization, 167--168, 170*of Haemophilus somnus*, 220hypersensitivity reactions to, 688--690immune stimulating complexes and, 405, 406, 407, 408--409multideterminant, 115produced by virus vectors, 148, 467, 473recognition, 182--184T cell-recognized, identification of, 186--187unconventional interactions with antibodies, 128VH chains and, 121Antigen-antibody complexes, 510Antigenic competition, 121--122Antigenic diversity in bovine virus diarrhea virus, 208factors effecting vaccination, 660vaccine failure and, 129, 695Antigen presentation cholera toxin adjuvanticity and, 92DNA immunization and, 165in vaccine development, 665Antigen presenting cells, *see also* Afferent lymph veiled cells; Dendritic cellsadjuvants and, 407cholera toxin and, 93immune stimulating complexes and, 410impact on T cell responses, 186plasmid-induced immunity and, 167T cell responses and, 275--276Antigen processing, intracellular pathways, 184--185Anti-laminin antibodies, 738--739, 742, 743, 744α*1*-Antiprotease, 648Antiserum, in acute phase protein assays, 649*Aphtovirus*, 198; *see also* Foot-and-mouth disease virusAquaculture, *see also* Fish; Fish vaccines antibiotics and, 540, 542--543infectious diseases and, 539--540productivity of, 539vaccines and, 540, 550Arboviruses, 29Arteritis, 390Arteriviruses, 363, 448Arthus reaction, 689ASC probes, 243--244Aspergillosis, 499*Aspergillus flavus*, 499*Aspergillus fumigatus*, 499*Aspergillus niger*, 499Assays, *see specific types*Astroviruses, 430Atheresclerosis, 56Atlantic salmon, *Vibrio viscosus* and, 544, 546--547Atrophic rhinitis vaccines, 420, 421, 422--423, 427Attenuation in early vaccinology, 12--16live, virus vectors and, 149--151Aujeszky\'s disease, 451, 464; *see also* Pseudorabies virusAutoantibodies, in vaccine-induced autoimmunity experiments, 738--745Autogenous vaccines, licensing of, 592--593Autoimmune disease, *see also* Immunemediated disease; *specific diseases* vaccine-induced, 690, 705--705, 720--721, 723, 734--745Autoimmune hemolytic anemia, 717, 719--720, 734; *see also* Immune-mediated hemolytic anemiaAutoimmune thyroiditis, 720, 723, 742Auxotrophic vaccines, tuberculosis and, 138--139Avian botulism, 554--555Avian immune system, 487--490Avian influenza vaccines, 521Avian leukosis viruses, 482Avianpox virus vectors in mammalian hosts, 476in recombinant vaccines, 467--469Avian Products Standardization Committee, 612*Avipoxvirus*, 518
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Bacille Calmette-Guérin vaccine, 135, 136, 141*Bacillus anthracis*, 17; *see also* AnthraxBacteremia, in *Bartonella henselae* infection, 340Bacterial antigens, in B cell evolution, 123Bacterial polysaccharides, homology withHIV-1 envelope, 127--128Bacterial vectors, *see also* Salmonella vectors for mucosal vaccines, 108--109, 110--111for transmissible gastroenteritis vaccines, 440Bacterins for clinical coliform mastitis, 265--267hypersensitive reactions to, 689--690licensing procedures, United States, 587--593*in ovo vaccination* and, 511--512for *Staphylococcus aureus*, 258--260, 261--262Badgers, 552*Bartonella henselae*, 335, 338--340, 342Batch control/release European regulation of, 602 in pseudorabies vaccines, 624Bat-eared foxes, 553Bats, as rabies carriers, 29, 34B cells, *see also* Antibody-secreting cells antigenic competition and, 121--122in avian immune system, 487, 488, 490cholera toxin and, 85clonal dominance and, 120evolution in, bacterial antigens and, 123gangliosides and, 85HIV-1 infection and, 119--120, 123immune stimulating complexes and, 408, 409immunodominant epitopes and, 128impairment of, in periparturient cows, 72isotype differentiation in, cholera toxin adjuvanticity and, 92--93in mucosal immune response, 434, 435self-reactive, in vaccine-induced autoimmunity, 743--744trafficking and, 63, 69VH genes and, 120--121Beagles, vaccine-induced autoimmunity and, 735--745Bias in adverse event report data, 755--757, 769in postmarketing surveillance, 753Bicinchoninic acid reaction, 648, 649Bicistronic plasmids, 168Biogeography, effects on vaccination, 662*Biologicals* (journal), 611Biotechnology recombinant vaccines and, 521--522, 581--582vaccine development and, 182, 517, 665Birds, *see also* Poultry type C botulism and, 554--555Black-footed ferrets, 552, 559Blastogenesis, suppression, in blood lymphocytes, 687Blood lymphocytes, suppression of blastogenesis in, 687Blowflies, 554Blue catfish, *see* Catfish"Blue eye," 314, 689Blue tongue virus, 718Bone marrow, immune response in, 408, 409Booster vaccinations, *see* Annual vaccinations; Revaccination*Bordetella bronchiseptica* canine distemper and, 20--21kennel cough and, 315--316*Bordetella bronchiseptica* vaccines, 316, 420, 423, 427*Borrelia burgdorferi*, 316--317, 368--369; *see also* Lyme disease*Borrelia hermsii*, 369*Borrelia theileri*, 369Botulism, Type C, in wild animals, 553--555Bovine herpesvirus 1 diagnostics for, 205--206distribution, 659early detection of, 31economics of vaccination for, 661eradication of, 197, 206--207herd immunity and, 210--211Bovine herpesvirus 1 vaccines administering with other vaccines, 695efficacy of, 202--204marker vaccines, 201--202overview of, 201residual virulence and, 686safety of, 204--205vaccine-induced immunosuppression and, 687Bovine leukemia, 40Bovine leukosis virus, 29, 31Bovine mastitis diagnostics for, 267--268, 269economics of, 257, 266etiologic agents of, 258Bovine mastitis vaccines for clinical coliform mastitis, 264--267difficulties in, 257--258, 268economics of, 257, 266*Mycoplasma bovis* and, 263overview of, 268--269polyvalent, 261for *Staphylococcus aureus*, 258--262for *Streptococcus agalactiae*, 261, 262*Streptococcus dysgalactiae* and, 262--263for *Streptococcus uberis*, 261, 263--264Bovine respiratory disease, 207--208Bovine respiratory syncytial vaccines, 689Bovine respiratory syncytial virus CD8 T cells and, 277characteristics of, 187--188immune response to, 188--191, 192Bovine serum, in vaccines, cross-reactivity and, 743, 745Bovine trichomoniasis, *see Tritrichomonas foetus*Bovine tuberculosis, *see* TuberculosisBovine vaccines, *see also specific vaccines* contamination of, 717Bovine venereal campylobacteriosis, *see* CampylobacteriosisBovine viral diseases ecology of infection and, 29eradication of, 197--198posteradication period and, 210--211Bovine virus diarrhea vaccines efficacy of, 208onset of immunity and, 211overview of, 207--208safety of, 208--209triggering of mucosal disease by, 690--691vaccine-induced immunosuppression and, 207, 687Bovine virus diarrhea virus antigenic diversity and, 660CD4 T cells and, 277in contamination of bovine vaccines, 717diagnostics for, 209distribution, 659eradication of, 197, 209--210Breeders, canine, vaccine use and, 291Breeds, *see* DogsBronchial lymph nodes enteropathogenic viruses and, 433, 436--439functional compartmentalization in, 439"Brooder pneumonia," 499*Brucella abortus*, 218--219, 232*Brucella abortus* vaccines, 524--525, 532Bulls campylobacteriosis and, 230trichomoniasis and, 225Burdon-Sanderson, J.S., 15, 22Bursa of Fabricius, 487, 488, 507, 511Bursaplex, 507--509
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Calciviruses, 3*Camplylobacter fetus* subsp. *venerealis*, 221--224Campylobacteriosis, *see also* Vibrosis diagnosis of, 223--224evasion of host defenses by, 223, 231genital mucosal inductive sites of, 228--229immune response to, 222--223, 228, 230pathogenesis of, 221--222similarity with trichomoniasis, 224vaccine development and, 233*Campylobacter jejuni*, 512Canarypox virus vector, 151, 153Canine adenovirus type 1, 314, 726Canine adenovirus type 1 vaccines, 294--295 "blue eye" and, 314, 689Canine adenovirus type 2, 314, 315Canine adenovirus type 2 vaccines for canine adenovirus type 1, 314canine hepatitis and, 302--303overadministration of, 728overview of, 315Canine coronavirus, 349 antibody-dependent enhancement and, 351in canine parvovirus mixed infections, 301, 313outbreaks of, 302overview of, 300--301Canine coronavirus vaccines efficacy and, 291overview of, 301--302, 313--314in polyvalent canine distemper vaccines, 294safety issues and, 293Canine distemper encephalitis, 294--295, 296, 301--302, 312Canine distemper vaccines, *see also* Mink distemper vaccines annual vaccination and, 5, 295, 303canarypox virus vector and, 153development of, 8duration of immunity and, 295, 296, 726early vaccines, 17--22efficacy issues and, 293maternal antibodies and, 294, 295minimal immunizing dose for, 294, 295, 296overview of, 311--312in polyvalent vaccines, 294--295, 301--302, 314postvaccinal encephalitis and, 294--295, 296, 301--302, 312production of, 293--294protective titers for, 726--727recombinant, 296, 312residual virulence and, 686, 687safety issues and, 293success of, 302wild animals and, 552--553Canine distemper virus, *see also* Mink distemper clinical course of, changes in, 568distribution, 659first isolation of, 19future research and, 567--568induced outbreaks and, 566--567infectious period in, 565--566production of inclusion bodies by, 561in wild animals, 551--553Canine hepatitis, 302--303, 314Canine herpesvirus, 26Canine measles, *see* Canine distemperCanine parainfluenza virus, 315Canine parvovirus, 411, 659, 661Canine parvovirus type 2, 298--299, 301, 312--313Canine parvovirus type 2 vaccines administration to pups, 297--298, 299--300efficacy and, 291, 298--300immunity duration in, 296--297, 300immunosuppression and, 298maternal antibodies and, 297, 313in polyvalent vaccines, 314revaccination and, 303safety and, 300types of, 296--297Canine parvovirus vaccines adverse reactions to, 722age at first administration, 661contamination of, 718duration of immunity and, 726efficacy and, 293overview of, 312--313protective titers for, 726--727virus-antibody complexes and, 510Canine rotavirus, 718Canine vaccines, *see also specific vaccines* disease outbreaks, nonvaccinated populations and, 291, 319efficacy of, 291--292, 293frequency of administration, 303, 310, 318history of, 309intranasal administration, 310modified live virus strains and, 292--293, 309--310overview of, 309--310, 318--319public awareness of, 289--291, 304quality of, 304recombinant, 292safety issues and, 291, 293in small animal practice, 290successes of, 302--303Caprine arthritis-encephalitis, 29Capsular polysaccharide, type 5, 261Capsular proteins, 260, 261Carbohydrate antigen type 1, 46, 48Carbohydrate antigen type 5, 46, 48Carré, H., 21, 22Carrier organisms, *see* Bacterial vectors;Virus vectorsCaseous necrosis, 140Catfish, *Edwardsiella ictaluri* and, 524, 525--535Cats adverse vaccine reactions in, 717*Bartonella henselae* and, 338--340factors affecting vaccination in, 660--661feline infectious peritonitis vaccination and, 353*Helicobacter pylori* and, 341overvaccination and, 718protective titers for, 727*Toxoplasma gondii* and, 336--338vaccine-induced fibrosarcomas and, 5, 704--705, 709*Yersinia pestis* and, 342zoonotic pathogens and, 335--342Cat scratch disease, 338--340; *see also Bartonella henselae*Cattle acute phase proteins in, 646botulism and, 554class I MHC genes in, identification of, 190DNA vaccines and, 175immunization development and, 285stress-related immunosuppression in, 71--74T cells in CD45 subpopulations, 278--282dendritic cell-induced responses, 284--285γδ T cell activation and function, 282--284γδ T cell trafficking, 64identification of subpopulations, 276*in vivo* roles of, 276--278vaccine contamination and, 717vaccine costs and, 175vaccine-induced mucosal disease in, 690--691Causality, concepts of, 754--755CD11a/CD18 integrin, 67--68, 69CD11b/CD18 integrin, 62, 68CD31 immunoglobulin, 69CD45 antigen, in T cell subpopulations, 278--282CD62E adhesion molecule, 63, 66CD62L adhesion molecule γδ T cells and, 64, 73glucocorticoids and, 73--74leukocyte trafficking and, 62, 66, 67, 69, 70CD62P adhesion molecule, 63, 66Cell death, in B cells, rescue from, 744Cell-mediated immune response, *see also* Cytotoxic T cell immune responsein avian immune system, 489--490in disease resistance, 42DNA immunization and, 165feline infectious peritonitis and, 350heritability and, 43herpesviruses and, 454--455immune-response selected pigs and, 45--46, 48--49modulation by interleukin 12, 450, 455--456in protective immunity, 524pseudorabies virus vaccines and, 451--452, 455--456suppression of during pregnancy, 71--72*Toxoplasma gondii* and, 337tuberculosis and, 137--138Cell surface receptors, *see* IntegrinsCellular compartments, plasmid-induced immunity and, 168Center for Veterinary Biologics, 627, 682 adverse event report data and, 771licensing procedures and, 587--588units within, 586--587vaccine efficacy and, 751Center for Veterinary Medicine, 771Cerebellar hypoplasia, 687Ceruloplasmin, 648Challenge trials bovine herpesvirus 1 vaccines and, 202--203for clinical coliform mastitis vaccines, 266leading to vaccine failure, 694in licensing procedures, 589for mink distemper vaccine, 560--561for *Streptococcus uberis* vaccines, 263--264swine vaccines and, 420vaccine efficacy and, 751Channel catfish annual production of, 539*Edwardsiella ictaluri* and, 524, 525--535beta-Chemokines, 411Chick cell agglutination test, 603Chicken embryo propagated vaccines, for mink distemper, 558--564Chickens, *see also* Poultry immune system of, 487--490Chinese Shar Pei dogs, 721Chlamydia, 29, 31*Chlamydia psittici*, 31; *see also* PsittacosisChloride ion concentration test, 267Cholecystokinin, immune-induced anorexia and, 56--57Cholera toxin adjuvanticity of, 85--98, 99, 106dual-signal integration and, 94interleukin 1 and, 94--96interleukin 12 and, 97--98SBR-CTA2/B, 106--109structure of, 84A subunit, 84--85, 106Cholera toxin, B subunit activity of, 84, 85, 92, 93adjuvanticity of, 106, 110, 111cholera toxin adjuvanticity and, 86--92, 99dual-signal integration and, 94immunogenicity of, 85, 86interleukin 1 and, 94--96interleukin 12 and, 97--98Chromogen, 648Chromogenic limulus amebocyte lysate test, 267Chronic fatigue syndrome, 73*Clarius batrachus*, 525Class I antigen processing, 184--185Class II antigen processing, 184--185Clearance*Edwardsiella ictaluri* RE-33 vaccine and, 529, 531, 532, 534 role of antibodies in, 168--169Climate, effects on vaccination, 662Clonal dominance, deceptive imprinting and, 118, 120, 122Clonal expansion, in deceptive imprinting, 119Clostridiosis vaccine, 421*Clostridium botulinum* Type C, 553--555*Clostridium perfringens* C vaccine, 420Coccidiosis, 512Codified efficacy testing, 635Cold-water vibrosis, 547Colibacillosis vaccine, 421, 422, 426Colic, 395, 399Coliform mastitis, clinical, 264--267, 269Color genes, in mink, distemper mortality and, 567--568Combined vaccines, *see* Polyvalent vaccinesCommittee for Veterinary Medicinal Products, 385--386, 596--597Common mucosal immune system, 434--435Companion animals benefits of DNA immunization and, 175risk management for, 709use of vaccines for, 290vaccine safety concerns and, 701--702Compartments, cellular, plasmid-induced immunity and, 168Complete Freund\'s adjuvant, *see* Freund\'s adjuvant, completeConcomitant immunity, 117Conditional licenses, 591Conjugated linoleic acid, immune-induced wasting and, 55--56Contagious equine metritis, 370--371Conventional antigens, 121Core antigen vaccines, for clinical coliform mastitis, 265--267, 269Corneal edema, 689*Cornyebacterium equi*, 372Coronaviruses, 349, 430, 431; *see also* Canine coronavirus; Feline coronavirus; Porcine respiratory coronavirusCorticosteroids, in treatment of vaccine-associated disease in dogs, 724Cortisol, vaccine-induced autoimmunity and, 738Costimulatory molecules, *see* AdjuvantsCowpox, 8, 9, 10, 11*Coxiella burnetti*, 342Coyotes, controlling rabies in, 580--581Crohn\'s disease, 96*Cryptosporidium parvum*, 96, 342*Culicoides* spp., 365Culture filtrate fraction vaccine, 140Cutaneous lymphocyte-associated antigen, 62, 70Cyclic AMP (cAMP), cholera toxin and, 84--85Cysteine proteases, 231 of liver fluke, 244--245, 246Cytokine assays, acute phase protein assays and, 646Cytokines acute phase proteins and, 645--646as adjuvants, 5, 448--449, 457--458, 486--487CD45 T cell subpopulations and, 279--280 cholera toxin induction of, 85, 93effects of glucocorticoids on, 73--74excessive induction of, 687--688in helminth-induced responses, 246ICAM-1 expression and, 68immune-induced wasting and, 54, 55in immune-response selected pigs, 46induction by immune stimulating complexes, 410in mucosal adjuvanticity, 94--99in periparturient immunosuppression, 71--72SBR-CTA2/B chimeric cholera toxin protein and, 108stimulation of selectin expression by, 66--67in *Strongylus vulgaris* infections, 391, 397, 400--402Cytomegalovirus, 450Cytotoxic T cell immune response, *see also* Cell-mediated immune response in bovine respiratory syncytial virus immunity, 189, 190--191, 192DNA immunization and, 166, 175epitope recognition in, MHC polymorphism and, 183feline immunodeficiency virus vaccines and, 327immune stimulating complexes and, 407pseudorabies virus vaccines and, 451--452
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Dairy cattle, *see also* Cattle disease resistance traits, heritability of, 41Deceptive imprinting B cell abnormalities in, 119--122described, 117, 118function of, 129HIV-1 modeling of, 117--119primary response to HIV-1 infection and, 123--128suppression of T cell polyclonal response in, 122vaccine failure and, 129--130Delayed-type hypersensitivity immune response cutaneous, in immune-response selected pigs, 43, 44immune stimulating complexes and, 410tuberculosis and, 138Deletion mutations in live attenuation of virus vectors, 150in marker vaccine design, 201Dendritic cells, *see also* Afferent lymph veiled cells induction of T cell responses by, 282--284plasmid-induced immunity and, 167virus--antibody complexes and, 511Depression, 395*Dermatophilus congolense*, 10Dexamethasone, 72--73, 73, 74Diagnosis concepts of causality and, 754--755distinguished from infection detection, 27--31Diagnostic medicine future of, 34--36infection detection and, 25--26, 28--31methods in, 31--32predictive value of preclinical testing in, 33--34traditional approaches to, 26--28Diagnostic tests, *see also individual tests*; Preclinical testing controlling disease transmission and, 360, 372future of, 34--36indirect, enzyme-linked immunoabsorbent assays and, 372in infection detection, 26international reference reagents and, 676--677levels of sensitivity in, 32OIE Standards Commission and, 672--677, 678Diapedesis, 65, 68Diarrheal disease enterpathogenic viruses and, 430, 433in swine, economic costs of, 464--465DiGeorge\'s syndrome, 452Dilutents, 693Diptheria-tetanus-pertussis vaccine, 734Disease, *see* Autoimmune disease; Diarrheal disease; Exotic disease; Immune-mediated disease; Infectious disease; Sexually transmitted disease; Zoonotic diseaseDisease prevention, *see also* Preventive medicineepidemiological approach to, 415--417role of vaccines in, 666Disease resistance, genetic predisposition and, 39--49Disease transmission, *see also* Mosquito-transmitted viruses; Sexually transmitted disease; Tick-borne disease; Transmissibility; Virus shedding controlling with vaccination, 664of distemper in ferrets, 564eradication of carrier states and, 175--176feral swine and, 464fleas and, 339--340long-distance, horses and, 359--360, 372, 379--380Distemper, *see* Canine distemper; Mink distemperDistemper vaccines, *see* Canine distemper vaccinesDNA, immunomodulatory effects of, 170DNA immunization antibody isotypes and, 168--169development of, 163--164DNA integration and, 164, 173DNA persistence and, 173DNA shedding and, 173economics of, 175efficacy of, 164exotic diseases and, 175--176future of, 174--176humoral immune response and, 164, 165induction of immunity and, 166--168injection site reactions and, 169, 175mucosal immune system and, 169--170, 175passive antibodies and, 171--172, 174polyvalent, 174--175regulatory issues and, 172--173universality of, 164--166vaccine delivery in, 169--171DNA technology, *see* Biotechnology; DNA immunizationDNA vaccines, 4 for feline immunodeficiency virus, 329for poultry, 520--521tuberculosis and, 140--141DNA virus vectors, 147Doberman pinschers, 661Dog owners, vaccine use and, 291Dogs adverse vaccine reactions in, 719--725, 728overvaccination and, 718susceptibility to disease and, 661vaccine-induced autoimmunity and, 705--706, 734--745Dosages, *see* Minimal immunizing doseDrenching, 250Drug residues, 664Drug resistance, 664Dual-signal integration immune response, 93--94Dunking, G.W., 22Duration of immunity, *see* Immunity, duration ofDusting, mink distemper vaccine and, 562
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Ear, DNA vaccine delivery and, 170Eastern equine encephalitis, 364Ecchymotic hemorrhages, *see* Immunemediated thrombocytopeniaEcology of infection, 29--31Ecosystems, effects on vaccination, 662*Edwardsiella ictaluri*, 523; *see also* Enteric septicemia of catfish bacterins, 524, 525EILO isolate, 525, 532*Edwardsiella ictaluri* RE-33 vaccine characteristics of, 527--528clearance and, 529, 531, 532, 534production of, 525--527protective immunity and, 531--531, 534--535reversion to virulence and, 529safety and, 528--529, 534Effector cells, in helminth-induced responses, 245Efficacy, *see* Vaccine efficacy; Vaccine efficacy testingEgg injection equipment, 497--498; *seealso* Inovoject egg injection systemEggs, *see also In ovo* vaccination hatchability, 500--502*in ovo* vaccine delivery and, 485, 490*Ehrlichia equi*, 368*Ehrlichia ristcii*, 368Ehrlichiosis, 26, 368, 662EIA test, 124, 126, 127*Eimeria tenella*, 512ELISAs, *see* Enzyme-linked immunoabsorbent assaysELISPOT assay, 455Embryos, *see In ovo* vaccinationEncephalitis*Bartonella henselae* and, 339 caprine arthritis-encephalitis, 29equine, 364polyvalent parvodistemper vaccine and, 5postvaccinal, canine distemper vaccines and, 294--295, 296, 301--302, 312*Toxoplasma gondii* and, 336Encephalomyelitis, 464Endogenous antigen processing, 184--185Endometrium, bovine trichomoniasis and, 229Endothelium CD31 immunoglobulin and, 69leukocyte trafficking and, 61--62, 65selectins and, 67Endotoxins, *see also* Lipopolysaccharides excessive cytokine induction and, 688*Haemophilus somnus* infection and, 220Enteric infections, *see also* Enteropathogenic viruses oral immunization and, 476in swine, economic costs of, 464viral, vaccination and, 433Enteric redmouth disease, 540, 543--544Enteric septicemia of catfish causative agent, 523*Edwardsiella ictaluri* RE-33 vaccine and, 525--535protective immunity and, 525Enteric vaccines, 433--434, 475Enterocytes, 410, 429, 430Enteropathogenic viruses, *see also* Enteric infections characteristics of, 430--434diarrhea and, 430enteric vaccines and, 433--434group A rotavirus vaccines and, 440--442mucosal immune response to, 434--442oral vaccines and, 429--430pathogenesis of, 431--433transmissible gastroenteritis virus vaccines and, 439--440Enterotoxins, *see also* Cholera toxin; Heat-labile toxin mucosal adjuvanticity and, 106Envelope glycoproteins, *see* GlycoproteinsEnzyme-linked immunoabsorbent assays (ELISAs) antibody detection and, 372in bovine herpesvirus 1 diagnostics, 205--206in bovine mastitis diagnostics, 268, 269in bovine virus diarrhea virus diagnostics, 209in foot-and-mouth disease diagnostics, 200in *Haemophilus somnus* diagnostics, 231in poultry antibody detection, 488, 489in *Strongylus vulgaris* antibody detection, 396--397in trichomoniasis diagnostics, 231Eosinophilia, 246 interleukin 5 and, 400in *Strongylus vulgaris* infections, 390--391, 396Epidemiology concepts of causality and, 754--755impact on vaccination, 660, 666input to immunoprophylaxis, 415--417in vaccine risk assessment, 704--706, 710Epinephrine, 637Epithelium genital, bovine trichomoniasis and, 230gut-associated, interleukin-1 and, 94mucosal, immunoglobulin A and, 111Epitopes, 115; *see also* Immunodominant epitopes diversity and, 660effects on DNA immunization, 170masking of, 129T cell recognition of, 183T cell-recognized, identification of, 186--187Epizootics equine influenza and, 379equine salmonellosis and, 371rabies and, 576Epstein-Barr virus, 411Equine abortion virus, 361--363Equine arteritis virus, 363--364Equine coital exanthema, 362Equine ferritin, 73Equine herpesviruses, 361--363, 411Equine infectious anemia, 29, 33, 366Equine Influenza Surveillance Programme, 380--386, 603Equine influenza vaccines, 361 antigenic drift and, 381--382, 384efficacy of, 380Equine Influenza Surveillance Programme and, 380--386licensing of, 382--383, 385--386, 602--604Equine influenza virus causative agent of, 360diagnosis of, 361emerging strains, 381--382, 384, 603epizootics and, 379Equine Influenza Surveillance Programme and, 380--386, 603long-distance transmission of, 379--380Equine metritis, contagious, 370--371Equine monocytic ehrlichiosis, 368Equine rabies, 367Equine rhinopneumonitis virus, 361--363Equine rotaviruses, 367Equine variola, 11; *see also* HorsepoxEradication of bovine herpesvirus 1, 197, 206--207of bovine virus diarrhea virus, 197, 209--210of foot-and-mouth disease virus, 197, 200--201as goal of vaccination, 474posteradication period and, 210--211Erysipelas vaccines, 420, 421, 422, 426*Escherichia coli, see also* Heat labile toxinO157:H7, preclinical detection and, 26 vector for transmissible gastroenteritis virus vaccine, 440*Escherichia coli* bacterins, 420 for clinical coliform mastitis, 265--266, 269Europe, wildlife reservoir species of rabies in, 572European Agency for the Evaluation of Medicinal Products, 596--597European ferrets, 559European Pharmacopoeia, 604--606 equine influenza vaccines and, 382, 385pseudorabies vaccine licensing and, 616, 624European Union, 659 clinical swine fever and, 661--662economics of bovine herpesvirus 1 vaccination and, 661licensing procedures, 595--596, 607centralized and decentralized registration in, 597--598definitions of veterinary biologicals in, 598--600for equine influenza vaccines, 602--604European Agency for the Evaluationof Medicinal Products and, 596--597for manufacturing authorization, 601--602pre-existing products and, 600--601for pseudorabies vaccines, 615--625role of European Pharmacopoeia in, 604--606Evan\'s syndrome, *see* Immune-mediated thrombocytopeniaEvolution in B cells, 123in viruses, 2--3Exogenous antigen processing, 184--185Exotic animals, canine distemper virus and, 552, 553Exotic disease, eradication of, 175--176, 210--211Extended quasi-likelihood function, 769
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Falvivirus, 364*Fasciola hepatica, see* Liver flukesFeedback loops, positive, in host-parasite relations, 249--250Feline calicivirus, 666, 727Feline coronavirus, 348, 349--350, 351, 355; *see also* Feline infectious peritonitisFeline coronavirus vaccine, 351--356Feline enteric coronavirus, 301, 349Feline herpesvirus, 5--6, 727Feline immunodeficiency vaccines, 326--329Feline immunodeficiency virus, 325--326Feline infectious peritonitis vaccine, 348 benefits of, 353--356description of, 351hypersensitive reaction to, 689overvaccination and, 718risks of, 352--353Feline infectious peritonitis virus, 348--349 antibody-dependent enhancement and, 351, 352--353, 354, 355canine coronavirus and, 301causative agent of, 348--349current status of, 348exposure dose for, 355forms of, 350historical perspectives on, 347--348immune response to, 350overvaccination and, 718pathogenesis of, 349--350preclinical detection and, 26, 33Feline leukemia vaccines, 573, 636, 728Feline leukemia virus, 27, 411, 718Feline panleukopenia, 313, 687, 727Feline parvovirus, 659Feline Sarcoma Task Force, 753Feline upper respiratory disease, 3Feline vaccines, vaccine label safety statements and, 638Feline viral rhinotracheitis, 686Fennec foxes, 552, 553Feral swine, disease transmission and, 464Ferrets distemper and, 558, 564, 565, 566--567maternal antibodies and, 562--563mink distemper vaccine and, 559, 560, 561--563, 564neonatal and transplacental immunization in, 564Ferry, N.S., 19--21, 22Ferry vaccine, 19--21Fetlocks, disease of, 10Fibronectin, 742; *see also* Anti-fibronectin antibodiesFibronectin-binding receptors, 261Fibrosarcomas, vaccine-induced aluminum hydroxide adjuvant and, 4--5epidemiological surveillance of, 704--705risk management for, 709vaccine label safety statements on, 638Field trials bovine herpesvirus 1 vaccines and, 204in licensing procedures, 589of pseudorabies vaccines, 620, 623Fish, *see also* Aquaculture; Catfish *Aeromonas salmonicida* and, 547--548*Edwardsiella ictaluri* and, 523*Vibrio anguillarum* and, 548*Vibrio salmonicida* and, 547Fishes Disease Commission (Office International des Epizooties), 672Fish vaccines advantages of, 550in aquaculture, 540benefits of, 542--543for enteric redmouth disease, 543--544for enteric septicemia of catfish, 525--535immune response to, 550methods of administering, 541--542polyvalent, 547--549for *Vibrio viscosus*, 544, 546--547Fleas, transmission of *Bartonella henselae* and, 339--340Flesh flies, 554"Floppy flipper disease," 554Florida, controlling raccoon rabies in, 579--580Foals, *Rhodococcus equi* and, 372Food and Agriculture Organization (United Nations), 659, 677Food and Drug Administration (United States), 771Food Security Act (United States), 627Foot and Mouth Disease and other Epizootics Commission (Office International des Epizooties), 672Foot-and-mouth disease vaccine, 198--200Foot-and-mouth disease virus antigenic diversity and, 660diagnostics for, 200eradication of, 197, 200--201failure to kill vaccine organism in, 685herd immunity and, 210synthetic peptide-stimulated immunity and, 184Formaldehyde, 685Fowl cholera, 13Fowlpox vaccine, 468Fowlpox virus vector, 153, 468--469, 486, 487, 518--519Foxes, 552, 553 controlling rabies in, 580--581*Francisella tularensis*, 342Frenkel, H.S., 198Frenkel vaccine, 198Freund\'s adjuvant complete compared to ISCOMs, 408--409in helminth vaccines, 246, 247*Staphylococcus aureus* vaccines and, 261, 262DNA vaccines and, 173incomplete, 227 transmissible gastroenteritis virus vaccines and, 440Furunculosis, 525, 543
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Gammaherpesvirinae, 362GangliosidesB cells and, 85 cholera toxin and, 84, 92, 95Gastric ulcers, *Helicobacter pylori* and, 341Gastroenteritis, 433Gastrointestinal immunization, 229Gastrointestinal nematode infections, 250--251; *see also* Trichostrongylid nematodesGeison, Gerald, 14Gene delivery, DNA immunization and, 165--166Gene expression, in virus vectors, 467, 468Gene gun, DNA vaccines and, 165, 170Genes, major, disease resistance and, 42, 43Genetics effects on health and vaccinations, 40--41health enhancement and, 39--40, 41--49susceptibility to vaccine-induced autoimmune disease and, 744--745Genetic testing, 32Gene vaccines, *see* DNA vaccinesGenital tract infections, bovine *Brucella abortus*, 218--219campylobacteriosis, 221--224*Haemophilus somnus*, 219--221overview of, 217--218*Tritrichomonas foetus*, 224--232*Giardia lamblia*, 342Glässer\'s disease vaccine, 421Glomerular amyloidosis, 722Glomerulopathy, 742--743Glucocorticoids bovine γδ T cells and, 64, 73in immunosuppression, 63--64, 70, 73--74stress-released, dexamethasone models of, 72--73Glutathione S-transferase, 244, 246, 247Glycoproteins acid soluble, assay for, 648clonal dominance and, 122in feline immunodeficiency virus vaccines, 326, 328in HIV-1 deceptive imprinting, 118, 120in Raboral V-RG vaccine, 574in swinepox recombinant vaccine, 474Good Manufacturing Practice, 601*gpt* gene, 471Gray foxes, 552 controlling rabies in, 580--581Gray seals, 552Grease, 9, 10--11Greenfield, William, 8, 15--17, 22Green sea turtles, 554Guaiacol, 648Guillain-Barré syndrome, 734Gumboro disease, *see* Infectious bursal diseaseGut-associated lymphoid tissue characteristics of, 83--84dual-signal integration immune response in, 93--94enteropathogenic viruses and, 433, 436--439functional compartmentalization in, 439interleukin 1 and, 94interleukin 12 and, 97mucosal adjuvanticity in, 92, 98--99in mucosal immune response, 435mucosal vaccines and, 108--109, 110--111
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H11 aminopeptidase, 245*Haemonchus contortus*, 242; *see also* Trichostrongylid nematodes antigen identification in, 243--244H11 vaccine and, 245 modeling of vaccines for, 251--253*Haemonchus placei*, 242*Haemophilus somnus* diagnosis of, 221, 232--233immune response to, 220--221pathogenesis of, 219--220virulence factors in, 220*Haemophilus somnus* vaccines, 232, 685--686*Halichoerus grypus*, 552Haptoglobin, 644, 650 assays for, 647--648, 649in cattle, 646in pigs, 646Harbor seals, 552Hatchability, *in ovo* vaccination and, 500--502*Hc-sL3* antigen, 243--244, 246*Hc-sL3* vaccine, 252, 253Health, *see* Animal health; Public healthHeat attenuation Pasteur and, 13--14Toussaint and, 12Heat-labile toxin adjuvanticity and, 106, 110immuogenicity of, 85--86structure and activity of, 84, 85in vaccines for transmissible gastroenteritis virus, 440*Helicobacter acinomyx*, 341*Helicobacter mustelae*, 341*Helicobacter pylori*, 341*Heligmosomoides polygyrus*, 401Helminthic infections, *see also Strongylus vulgaris* eosinophilia and, 391, 400interleukin 4 and, 400--401overdispersion and, 251Th2 immune response and, 391Helminthic vaccines adjuvants in, 246, 247development in, 241--242dynamics of gastrointestinal nematode infections and, 250--251economic importance of, 242future trends in, 253--254immune responses, 245--247modeling host-parasite population dynamics and, 247--250, 254modeling of *Haemonchus* vaccines, 251--253novel antigens and, 244--245protective antigens and, 242--245Hemagglutination inhibition test equine influenza and, 361protective titer levels and, 726--727Hemagluttinin gene, in equine influenza virus, 602Hematologic disease, *see* Autoimmune hemolytic anemia; Immune-mediated hemolytic anemia; Immune-mediated thrombocytopeniaHemoglobin, in assays for haptoglobin, 647--648Hemolytic anemia, immune-mediated, 705--706, 734Hemolytic assays, *see also* Single radial hemolysis test in trichomoniasis diagnostics, 231Hemorrhagic enteritis virus, 483Henle-Koch postulates, 754, 755Hepatitis contagious canis, *see* Canine hepatitisHepatocytes, acute phase proteins and, 645Herd immunity, 210--211, 664, 711Heritability, disease resistance traits and, 41Herpes simplex virus, 452, 454Herpesvirus(es) cell-mediated immune response and, 454--455equine, 361--363feline, 5--6, 727immune stimulating complexes and, 411porcine, economic costs of, 464of turkeysin Marek\'s disease vaccine, 496, 497, 498, 500, 502--503, 519in recombinant poultry vaccines, 486, 519Herpesvirus vaccines, 150Herpesvirus vectors, 150, 151, 475, 486, 519Heterotypic immunity, 117Hidden antigens, *see* Novel antigensHigh endothelial venules, 65High immune response phenotype, 43--49Hitra disease, 547; *see also Vibrio salmonicida*HIV-1, *see also* AIDS; Lentiviruses anamnestic recall response and, 127auxotrophic vaccines and, 139B cell abnormalities and, 119--120, 123deceptive imprinting model and, 117--119epitope masking and, 130feline immunodeficiency virus DNA vaccines and, 329immune stimulating complexes and, 411modeling with feline immunodeficiency virus, 325OAS phenomenon and, 116--117tuberculosis mortality and, 135viral envelope of, 127--128HIV-2, 411Hog cholera vaccine, 423Homeopathic nosodes, 305, 318--319, 716Homologous recombination in DNA integration, 173in recombinant vaccine formation, 471, 518, 574reversion to virulence and, 475Horsepox, 8, 9, 10--11, 22Horses bacterial diseases of, 368--372long-distance disease transmission and, 359--360, 372, 379--380Uasin Gishu pox and, 11vaccination and, 360, 373viral diseases of, 360--367, 371Host-parasite relations in gastrointestinal nematode infections, 250--251modeling vaccination in, 247--250, 254Huidekoper, R.S., 18Human adenovirus type 5, 151Human alpha-1 antitrypsin, 164Human growth hormone, 164Human immunodeficiency virus type 1, *see* HIV-1Human parainfluenza virus 2, 315Human reovirus, 510Humans *Bartonella henselae* and, 338--339, 340*Helicobacter pylori* and, 341*Microsporum canis* and, 342rabies and, 335, 571--572rotaviruses and, 430*Toxoplasma gondii* and, 335, 336--337, 338*Yersinia pestis* and, 342Human vaccines, *see also specific vaccines* as models for veterinary vaccines, 659reporting of adverse events in, 755--756success of, 657Humoral immune response in avian immune system, 488--489, 490cytopathic viruses and, 448in disease resistance, 42DNA immunization and, 164, 165feline infectious peritonitis and, 350heritability and, 43HIV-1 infections and, 119--120, 123--128immune-response selected pigs and, 45--49pregnancy and, 71pseudorabies virus vaccines and, 451--452HyMast test, 267--268Hypersensitivity reactions, 688--690 clinical overview of, 716--717Hypertrophic osteodystrophy, 724Hypothesis testing, of adverse event report data, 758, 764--766Hypothyroidism, 725
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*Ictalurus punctatus*, 524; *see also* Channel catfishIgA, *see* Immunoglobulin AIgE, *see* Immunoglobulin EIgG, *see* Immunoglobulin GIgM, *see* Immunoglobulin MImmersion vaccination, 541, 543--544, 549Immune complex type response, in hypersensitive reactions, 689--690Immune deficiency syndrome, in Weimaraners, 723Immune enhancement, *see* Antibody-dependent enhancementImmune-induced wasting, 53--57Immune-mediated disease, *see also* Autoimmune disease; *specific diseases* mechanisms of, 723vaccine-related, 705--706Immune-mediated hemolytic anemia, 705--706, 734; *see also* Autoimmune hemolytic anemiaImmune-mediated polyarthritis, 721Immune-mediated thrombocytopenia, 717, 719, 720--721Immune response, *see also* Cell-mediated immune response; Cytotoxic T cell immune response; Delayed-type hypersensitivity immune response; Humoral immune response; Secondary immune response to carrier organisms, 111dual-signal integration in, 93--94effects of stress on, 70--74gene-related, 40--41genetic enhancement of, 39--40, 41--49induction, DNA immunization and, 166--168in mucosal immune system, 111--112Immune response phenotype, 43--49Immune stimulating complexes (ISCOMs), 326 antigen presentation and targeting by, 407antigen transport by, 408--409conceptual design of, 406formation of, 406--407induction of cytokine Th1-Th2 response, 410induction of immune response in neonates, 410--411induction of mucosal immunity, 409--410induction of protective immunity, 411overview of, 405--406for rabies, 311Immune systems, avian, 487--490Immune tolerance, DNA immunization and, 171Immunity, *see also* Acquired immunity; Active immunity; Herd immunity; Protective immunity concomitant or heterotypic, 117inhibition of, immunoglobulin G and, 172mucosal, duration of, 663sterile, DNA vaccines and, 171Immunity, duration of for canine vaccines, 295, 296--297, 300, 310inadequate, vaccine failure and, 694--695for mink distemper vaccines, 559--560revaccination and, 663, 725--727Immunization, *see also* DNA immunization; Vaccination distinguished from injection, 5in poultry, 483prophylactic, *see* Immunoprophylaxissexually transmitted diseases and, 223use of synthetic peptides in, 183--184Immunoassays, *see* Acute phase protein assaysImmunocompromised systems, *see also* AIDS *Bartonella henselae* and, 339, 340infectious disease and, 334--335Immunodiffusion, 648--649Immunodominant epitopes in HIV-1 infection, B cell abnormalities and, 123masking of, 130OAS phenomenon and, 116--117pre-existing B cell clones and, 128in unconventional reactions with antibodies, 128--129vaccine failure and, 129Immuno-electron microscopy, 407Immunofluorescence, inclusion bodies and, 561--562Immunoglobulin A (IgA) in avian immune system, 488bovine trichomoniasis and, 226--228, 229campylobacteriosis and, 222--223cholera toxin induction of, 87, 93enteropathogenic viruses and, 436--439heat labile toxin and, 85--86mucosal epithelium and, 111mucosal immune response and, 112, 434, 435porcine group A rotaviruses and, 441--442respiratory syncytial virus and, 410SBR-CTA2/B chimeric cholera toxin protein and, 107Immunoglobulin A plasma cells, *see also*Antibody-secreting cells in mucosal immune response, 435Immunoglobulin E (IgE) in helminthic infections, 245, 400--401in hypersensitivity reactions, 689Immunoglobulin G (IgG) inhibited by active immunity, 172in avian immune system, 488bovine trichomoniasis and, 226--228, 229--230campylobacteriosis and, 222--223CD4 T cells and, 185DNA immunization and, 169*Haemophilus somnus* infections and, 220--221HIV-1 infections and, 124--127monoclonal populations in HIV infections, 119mucosal immune response and, 112plasmid-induced immunity and, 168SBR-CTA2/B chimeric cholera toxin protein and, 107*Staphylococcus aureus* infections and, 260--261*Strongylus vulgaris* infections and, 396, 399--400, 402suppression of T cell polyclonal response and, 122thymus-independent antigens and, 123Immunoglobulin M (IgM) in avian immune system, 488campylobacteriosis and, 223HIV-1 infections and, 124, 127thymus-independent antigens and, 123Immunoglobulins assays for, international standardization and, 652in avian immune system, 488cholera toxin induction of, 87, 93dexamethasone repression and, 73heat labile toxin and, 85--86HIV-1 infections and, 123--127leukocyte trafficking and, 68--69mucosal immune response and, 112SBR-CTA2/B chimeric cholera toxin protein and, 107in *Strongylus vulgaris* infections, 396--397, 399--400, 402Immunological veterinary medicinal product, *see* Veterinary biological productsImmunological Veterinary Medicinal Working Party, 597, 598Immunologic memory, *see also* Secondary immune response duration of immunity and, 726vaccine development and, 666Immunology origins of, 7--8vaccine development and, 182--187William Greenfield on, 15--16, 17Immunomodulators DNA as, 170licensing procedures for, 590--591virus vectors and, 148--149Immunoprophylaxis bovine campylobacteriosis and, 223bovine trichomoniasis and, 230epidemiological approach to, 415--417Immunosuppression avian viruses and, 483bovine virus diarrhea virus and, 207--208canine parvovirus type 2 vaccines and, 298causing vaccine failure, 694infectious disease and, 334--335residual virulence of modified live vaccines and, 686--687stress-related, 70--74vaccine-induced, 687Immunoturbidimetry, 649Inactivated bacterins excessive cytokine induction and, 688failure to kill vaccine organism in, 685--686Inactivated vaccines for canine parvovirus type 2, 296, 297, 313for canine viruses, 310cytokine adjuvants and, 457--458for equine influenza, 380failure to kill vaccine organism in, 685--686for feline immunodeficiency virus, 326--327, 328importance of, 457porcine pseudorabies virus and, 447--448, 451--452, 454, 455--456, 457for rabies, 310, 311risks of reversion and, 466Inclusion bodies, 561--562Incomplete Freund\'s adjuvant, *see* Freund\'s adjuvant, incompleteIndications, on vaccine labels, 637Infection acute phase proteins in, *see* Acutephase proteinsdistinguished from disease, 29ecology of, 29--31genetic predisposition to, 32Infection detection in diagnostic medicine, 25--26ecology of infection and, 29--31genetic predisposition to infection and, 32methods in, 31--32preclinical, 26, 28--29predictive value of, 33--34traditional approach to, 27--28Infectious bovine keratoconjunctivitis, 687Infectious bovine rhinotracheitis, 197, 201--207, 210--211; *see also* Bovine herpesvirus 1Infectious bronchitis vaccines DNA vaccines, 521maternal antibodies and, 506*in ovo* vaccination and, 503--504Infectious bronchitis virus, 482Infectious bursal disease vaccines, 507--509, 511Infectious bursal disease virus, 483Infectious canine hepatitis, *see* Canine hepatitisInfectious disease, *see also specific diseases* animal management and, 417in aquaculture, 539--540breed susceptibility and, 661in commercial poultry flocks, 482--483control of, diagnostics and, 360, 372distinguished from infection, 29economic costs of, in swine, 463--465emerging, 333, 334--335gene-related resistance to, 40--41"global," 659immunosuppression and, 334--335reemergence of, 333Infectious laryngotracheitis virus, 482Infectious pancreatic necrosis, 543Inflammation acute phase proteins and, *see* Acute phase proteinsleukocyte trafficking and, 61--62, 66--67, 68--69, 74mucosal immune response and, 111--112Influenza vaccines, *see also* Equine influenza vaccines avian, 521porcine, 421, 427Influenza virus, *see also* Equine influenza virusimmune stimulating complexes and, 410Injection, distinguished from immunization, 5Injection site reactions adjuvants and, 169, 620Arthus reaction and, 689causes of, 691DNA vaccines and, 169, 175with pseudorabies vaccines, testing for, 620Innocuity, 4--5Inovoject egg injection system, 495, 497--503*In ovo* vaccination aspergillosis and, 499automated equipment for, 497--498with bacterial vaccines, 511--512benefits of, 496field efficacy trials in, 498--499with fowlpox vaccines, 505history of, 495, 496with infectious bronchitis vaccines, 503--504with infectious bursal disease vaccine, 504--505with Marek\'s disease vaccines, 497--503, 512maternal antibodies and, 505--506moisture loss and, 502with Newcastle disease vaccines, 504overview of, 485, 490Rispens-type vaccines and, 502--503time of injection, 500--501upside down eggs and, 501--502vaccine preparation for, 499--500with virus--antibody complex vaccines, 506--511Integrinsβ2 family, 67--68α*4* family, 69--70 in leukocyte trafficking, 62--63, 67--68, 69--70Inter-American Institute for Cooperation on Agriculture, 677Intercellular adhesion molecules effects of dexamethasone on, 74leukocyte trafficking and, 62, 68--69Interferon, gamma as adjuvant, 458CD45 T cell subpopulations and, 279--280in cell-mediated immune response, 453--455inactivated pseudorabies virus vaccine and, 455--456induction by immune stimulating complexes, 410inhibition by interleukin 10, 401interaction with interleukin 12, 450in *Strongylus vulgaris* infections, 401--402Th1 immune response and, 185Interferons adjuvanticity in DNA immunization, 168DNA tuberculosis vaccines and, 140interleukin 12 and, 97in mucosal adjuvanticity, 98--99in periparturient immunosuppression, 71--72recombinant poultry vaccines and, 487Interleukin 1 immune-induced wasting and, 54, 55in mucosal adjuvanticity, 94--96, 98--99Interleukin 2 CD45 T cell subpopulations and, 279induction by immune stimulating complexes, 410Th1 immune response and, 185Interleukin 4 CD45 T cell subpopulations and, 279helminthic infections and, 400--401*Strongylus vulgaris* infections and, 397, 400--401, 402Interleukin 5 eosinophilia and, 400*Strongylus vulgaris* infections and, 397, 400, 402Interleukin 6 acute phase proteins and, 645excessive induction of, 687Interleukin 10 inhibition of gamma interferon by, 401inhibition of interleukin 12, 450*Strongylus vulgaris* infections and, 401Interleukin 11, acute phase proteins and, 645Interleukin 12 adjuvanticity of, 448, 449, 450, 455--456, 458modulation of acquired immune response, 449--450modulation of immune response to pseudorabies virus vaccine, 455--456in mucosal adjuvanticity, 96--99production and regulation of, 450structure of, 449--450Interleukins CD4 T cells and, 185cholera toxin-induced, 85dexamethasone repression and, 73helminthic infections and, 246inhibition of gamma interferon by, 401in mucosal adjuvanticity, 94--99in periparturient immunosuppression, 71--72*Strongylus vulgaris* infections and, 397, 400--402toxin induction of, 93*Toxoplasma gondii* infections and, 337*International Animal Health Code*, 673International Animal Health Code Commission (Office International des Epizooties), 672International Association of Biological Standardization, 609--614International organizations, *see also* European Union; Office International des Epizooties; World Health Organization in veterinary standardization, 659International trade diagnostic tests and, 673disease transmission in horses and, 359--360, 372, 379--380International Union of Microbiological Societies, 610Interval estimation, of adverse event report data, 763--764Intestines, pathogenesis of enteric viruses and, 431, 433Intradermal vaccination, DNA vaccines and, 165--166Intragastric vaccination mucosal immune system and, 106SBR-CTA2/8 chimeric cholera toxin protein and, 109, 110Intramammary infections, *see also* Bovine mastitis coliform vaccines and, 265*Staphylococcus aureus* vaccines and, 259, 260, 261Intramuscular vaccination, DNA vaccines and, 165, 170Intranasal vaccination canine vaccines and, 310mucosal immune system and, 106SBR-CTA2/8 chimeric cholera toxin protein and, 109, 110Intraperitoneal vaccination for fish, 541--542, 549of transmissible gastroenteritis virusvaccine, 440ISCOMs, *see* Immune stimulating complexesIsoelectric focusing, 120Ivermectin, 390*Ixodes dammini*, 662*Ixodes* spp., 316, 368
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Japanese encephalitis vaccine, 423Japanese equine encephalitis, 364Jenner, Edward, 465 canine distemper and, 17--18cowpox vaccine and, 9origin of vaccinology and, 7, 22vaccinia and, 8Jenner\'s vaccine, 9, 13

K {#cesec50b}
=

Kennel cough *Bordetella branchispetica* and, 315--316canine adenovirus type 2, 314canine distemper and, 20--21canine parainfluenza virus and, 315polyvalent nasal vaccination for, 315, 316Keyhole limpet hemocyanin cholera toxin adjuvanticity and, 87, 91, 92, 93in vaccine-induced autoimmunity experiments, 735, 737, 738, 740Kidney failure, *see* Renal failureKinkajous, 552Kramer algorithm, 771

L {#cesec50c}
=

L5 phage, 139Labels, *see* Vaccine labelingLabrador retrievers, 661*lacZ* gene, 471Laidlaw, P.P., 22Lamina propria, 436, 438, 439Laminin, *see* Anti-laminin antibodiesLangerhan cells, 167Latency testing, 636 in pseudorabies vaccines, 619Latent variables, 762Lebailly, C., 21*Leishmania major*, 185Lentiviruses, *see also* HIV-1 vaccine development for, 366Leopards, 553*Leptospira bratislava*, 371*Leptospira pomona*, 371Leptospirosis, 304, 317--318 equine, 371--372Leptospirosis vaccines duration of immunity in, 663efficacy and, 291, 303for swine, 420, 423, 426"Lesionless pathology," 31Lesions, at injection sites, *see* Injection site reactionsLeukocyte adhesion deficiency type 2, 67Leukocyte trafficking effects of stress on, 63--64, 70, 72--73, 74endothelium and, 61--62, 65importance of, 61integrins and, 62--63, 67--68, 69--70intercellular adhesion molecules and, 68--69molecular basis of, 62--63overview of, 65in periparturient immunosuppression, 72selectins and, 62, 65--67stress-released glucocorticoids and, 72--73Leukosis avian, 482, *see also* Marek\'s disease virusbovine, 29, 31LFA-1 integrin, 67--68, 69Licensing procedures (European Union), 595--596, 607 centralized and decentralized registration, 597--598definitions of veterinary biologicals in, 598--600for equine influenza vaccines, 382--383, 385--386, 602--604European Agency for the Evaluation of Medicinal Products and, 596--597for manufacturing authorization, 601--602pre-existing products and, 600--601for pseudorabies vaccines, 615--625role of European Pharmacopoeia in, 604--606Licensing procedures (United States) for autogenous products, 592--593conditional licensing and, 591for conventional vaccines and bacterins, 587--590exemptions to, 592for further manufacturing, 591--592for immunomodulators, 590--591for modified live pseudorabies vaccines, 628--632for recombinant products, 590sublicensing and, 592Virus Serum Toxin Act and, 585--586, 627Lifestyle, effects on vaccination, 660--661Limast test, 267Linoleic acid, conjugated, immune-induced wasting and, 55--56Lions, 553Lipophilic muramyl dipeptides, 169Lipopolysaccharide antigen type 1, 46, 48Lipopolysaccharides, *see also* Endotoxins excessive cytokine induction and, 688immune-induced wasting and, 56Live attenuated vaccines, *see also* Modified live vaccines described, 466for *Edwardsiella ictaluri*, 525--535for rabies, 311virus vectors and, 149--151Liver failure, vaccine-induced, 717Liver flukes, 242, 244--245, 246--247Loglinear modeling, of adverse event report data, 766--769Low immune response phenotype, 43, 45--48, 49Lowry reaction, 648, 649Loy, John, 10Lupus erythematosus, systemic, 706, 742, 743*Lycaon pictus*, 552*Lyme borreliosis, see* Lyme diseaseLyme disease, 662 etiologic agent, 316horses and, 368--369Lyme disease vaccine, 303--304, 316--317 overadministration of, 728recombinant, 573Lymph, dendritic cells in, 284; *see also* Afferent lymph veiled cellsLymph nodes AgI/II adhesin and, 108ISCOM antigen transport and, 408mesenteric, in mucosal immune response, 435, 436plasmid-induced immunity and, 167immune stimulating complexes and, 407proliferation, cholera toxin and, 93self-reactive, in vaccine-induced autoimmunity, 744suppression of blastogenesis in, 687Lymphocyte trafficking adhesion molecules and, 62--63integrins and, 69--70Lymphoid nodules, genital, bovine trichomoniasis and, 229Lymphoid system, avian, 487--4488Lymphoid tissue gut-associated, *see* Gut-associated lymphoid tissuenasal, immunization and, 110Lymphopenia, 687Lymphoproliferative assays, 436, 438, 439Lymphoproliferative response, to pseudorabies virus vaccines, 451--452Lyssavirus, 367, 371
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Mac-1 integrin, leukocyte trafficking and, 62, 68Macaques, HIV-1/SIV protection in, 411α2-Macroglobulin, 646, 648Macrophage cytokines, in mucosal adjuvanticity, 94--99Macrophage inflammatory protein, acute phase proteins and, 645Macrophages *Edwardsiella ictaluri* RE-33 vaccine and, 534in feline infectious peritonitis, 350, 351inhibition of by interleukins, 401ISCOM uptake by, 408Maggots, botulism and, 554Major acute phase protein, 647Major histocompatibility complex (MHC) cholera toxin adjuvanticity and, 92class I in antigen processing, 184, 185in antigen recognition, 182--183bovine respiratory syncytial virusimmunity and, 190--191class II antigenic competition and, 121in antigen processing, 184--185in antigen recognition, 182--183gamma interferon and, 453immune response and, 40, 43in mucosal adjuvanticity, 99polymorphisms in, 183T cell-recognized epitopes and, 187Mammary glands, in mucosal immune system, 435Mannose receptor, 121*Manual of Standards for Diagnostic Tests and Vaccines* (Office International des Epizooties), 672--674, 676, 677, 678Marek\'s disease vaccines, 485, 490 bivalent, 497herpesvirus of turkeys and, 496, 497, 498, 500, 502--503, 519International Association of Biological Standardization and, 612--613maternal antibodies and, 505 *in ovo* vaccination and, 496, 497--503, 512Rispens type, 502--503Marek\'s disease virus, 482 distribution, 659gene-related resistance to, 40, 41*in ovo* vaccination and, 496Rispens-type vaccines and, 502--503Marginal metallophilic macrophages, 408Marginal zone macrophages, 408Marine mammals, canine distemper virus and, 552Marker vaccines for bovine herpesvirus 1, 201--202defined, 201in disease eradication, 210Massachusetts, controlling raccoon rabies in, 578--579Master Cell Stock in licensing procedures, 588in pseudorabies vaccine licensing, 629Master Seeds in licensing procedures, 588, 590in pseudorabies vaccine licensing, 628--629Mastitis, *see* Bovine mastitis; Coliform mastitisMaternal antibodies, *see also* Passive immunity canine distemper vaccines and, 294, 295canine parvovirus type 2 vaccines and, 297, 313canine vaccines and, 310DNA immunization and, 171, 174effects on vaccination, 661feline immunodeficiency virus vaccines and, 327immune stimulating complexes and, 410--411infectious bursal disease and, 507kennel cough vaccines and, 315, 316mink distemper vaccine and, 562--563poultry vaccines and, 505--506recombinant Newcastle disease vaccine and, 519vaccine failure and, 693--694virus--antibody complex vaccines and, 506--511Maximum residue limits, 596M cells, 110, 435Measles vaccine, adverse reactions to, 717Measles virus, 312Meat qualityDNA vaccines and, 175 *Toxoplasma gondii* and, 338Memory immune response, *see* Immunologic memory; Secondary immune responseMemory lymphocytes, *see also* T cells, memorytrafficking and, 63, 70Memory T cells, *see* T cells, memoryMesenteric lymph nodes, in mucosal immune response, 435, 436MHC, *see* Major histocompatibility complexMicroorganisms, environmental, effects on animal performance, 53--54, 57*Microsporum canis*, 342Milk bovine herpesvirus 1 antibody detection and, 206bovine virus diarrhea virus detection and, 209Minimal immunizing dose for caninea vaccines, 294, 295, 296for mink distemper vaccines, 559Mink botulism and, 554botulism vaccine and, 555distemper vaccinees and, 558--564distemper virus and, 552, 557--558, 565--568enteritis vaccine and, 553enteritis virus and, 313Mitogen proliferation assays, 489Modified live vaccines, *see also* Live attenuated vaccines adverse reactions to clinical overview of, 716--717in polyvalent vaccines, 718--719, 722, 724canine, 296, 300, 309--310, 312, 314described, 292licensing of, 615--625, 628--632nonimmunizing mutants and, 293pseudorabies virus and, 447--448, 451--452, 454, 455residual virulence and, 686--687reversion and, 466Monocytes, afferent lymph veiled cells and, 284Monophosphoryl lipid A, 169Morbillivirus, 410, 551Mortality canine coronavirus and, 301human, rabies and, 571--572pseudorabies virus and, 464Mosquito-transmitted viruses, equine, 364, 365Moss, Bernard, 147Mouse hepatitis virus, mode of release in, 431Mucosal addressin cell adhesion molecule 1, 62, 70Mucosal adjuvanticity cholera toxin and, 84--92, 106dual-signal integration in, 93--94immune stimulating complexes and, 409--410interleukin 1 in, 94--96interleukin 12 in, 94--96mechanisms of, 92--98Mucosal disease, 207, 209 vaccine-induced, 690--691Mucosal epithelium, immunoglobulin A and, 111Mucosal immune system adjuvanticity in, *see* Mucosal adjuvanticitycharacteristics of, 83--84DNA vaccines and, 169--170, 175 immune responses in, 111--112immune stimulating complexes and, 409--410oral vaccines and, 105--106, 430overview of, 434--435response to enterpathogenic virusesand vaccines, 436--442virus vectors and, 149Mucosal immunity, duration of, 663Mucosal vaccines carriers organisms and, 110--111gut-associated lymphoid tissue and, 110--111*Salmonella* expressing SBR-CTA2/B and, 108--109 vaccine-induced autoimmunity and, 745Multideterminant antigens, 115Multivalent vaccines, *see* Polyvalent vaccinesMuramyl dipeptides, lipophilic, 169Murine cytomegalovirus, 450Muscle cells, transfected, plasmid-induced immunity and, 166*Mustela nicripes*, 552*Mustela putorius*, 559Mutants, nonimmunizing, in viral vaccines, 293Mutation in B cells, autoimmunity and, 744in canine parvovirus type 2, 313in live attenuation of virus vectors, 150in marker vaccine design, 201in viruses, 2--3Myasthenia gravis, 744Mycobacteria, as vectors, 138--139*Mycobacterium bovis, see* Tuberculosis*Mycoplasma bovis*, 263*Mycoplasma hyopneumoniae* vaccine, 421, 422*Mycoplasma hyorhinis*, 46Myoblasts, transfected, plasmid-induced immunity and, 166Myoglobin, autoantibodies and, 739, 741Myosin, of skeletal muscle, autoantibodies and, 739, 741
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NAGase test, 267Naive lymphocytes, trafficking and, 63, 70Nasal lymphoid tissue, 110Nasal shedding, *see also* Virus shedding bovine virus diarrhea virus and, 277National Environmental Policy Act, 590, 628, 631National Institute for Biological Standards and Controls, 382, 386Natural immunity, *see* Passive immunityNatural killer cells, *see also* Cytotoxic T cell immune response; T cellsin avian immune system, 489--490Negri bodies, 367Nematodes, *see also* Helminthic vaccines; Trichostrongylid nematodes gastrointestinal infections and, 250--251hidden antigens and, 245intestinal, interleukin-12 and, 96Neonates administration of canine vaccines and, 297--298, 299--300, 661adverse reactions and, 719diarrheal disease and, 464--465DNA vaccines and, 171gastrointestinal nematode infections and, 250--251immune stimulating complexes and, 410--411immunosuppression and, 71maternal antibodies and, 174swinepox virus and, 475--476timing of vaccination for, 661, 663, 694, 719Neoplastic disease avian, 482vaccine-induced, 690Neutralization tests in bovine herpesvirus 1 diagnostics, 205, 206in bovine virus diarrhea virus diagnostics, 209Neutrophilia, 67, 72Neutrophils CD31 immunoglobulin and, 69CD62L adhesion molecule and, 66, 74glucocorticoids and, 63in inflammatory response, 67in leukocyte trafficking, 62stress-released glucocorticoids and, 72--73Newcastle disease vaccines fowlpox virus vector and, 153maternal antibodies and, 506, 519*in ovo* vaccination and, 504recombinant, 486, 487, 518--519virus--antibody complexes and, 510Newcastle disease virus, 482, 518New Jersey, controlling raccoon rabies in, 576--578New York, controlling raccoon rabies in, 578, 580*Nippostrongylus brasiliensis*, 96Nonamphipathic proteins, 406Noncodified efficacy testing, 635--636Nonvaccinated animals disease outbreaks and, 291, 319herd immunity and, 711Norwood-Sampson test, 764--766Nosodes, 305, 318--319, 716Novel antigens, helminth vaccines and, 244--245, 246--247, 253Novel antigen vaccines, modeling of, 253Nucleic acid vaccines, *see* DNA vaccinesNutrition, immune-induced wasting and, 55--57
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OAS phenomenon, 116--119Office International des Epizooties (OIE)Equine Influenza Surveillance Programme and, 380--386 founding of, 670guidelines for veterinary laboratories, 676international reference reagents and, 676--677objectives of, 670organizational structure of, 670--672other international organizations and, 677reference laboratories and collaborating centers of, 675--676Sanitary and Phytosanitary Agreement and, 677, 678specialist commissions of, 672Standards Commission of, 670, 672--677, 678OIE, *see* Office International des Epizooties*OIE Bulletin*, 383--384, 603Old English sheepdogs, 720--721Omega-3 fatty acids, immune-inducedwasting and, 55Oncogenes, in disease prevention, 32*Oncorhynchus mykiss*, 525; *see also* Rainbow troutOnderstepoort canine distemper vaccinestrain, 293, 295, 312Oocyst shedding, *see also* Virus shedding in *Toxoplasma gondii* infections, 337--338Opiods, endogenous, in periparturientcattle, 71Oral vaccination for enteric pathogens, 476for fish, 542, 543--544, 549immune stimulating complexes and, 409--410mucosal immune system and, 105--106Raboral V-RG vaccine and, 572, 582recombinant viral vaccines and, 475for *Strongylus vulgaris*, 390Oral vaccines cholera toxin and, 84, 85, 86, 87--92enterpathogenic viruses and, 429--430heat labile toxin and, 85--86mucosal immune system and, 430Orbivirus, 365"Original antigenic sin," 118; *see also* OAS phenomenonOrmethoprim-sulfamethoxine, 524Orthopoxvirus, 11OspA vaccine, 303, 317, 369*Ostertagia circumcincta*, 242*Ostertagia ostertagi*, 242; *see also* Trichostrongylid nematodes*Ostertagia* spp., 245Ostriches, 481Ovalbumin, cholera toxin adjuvanticity and, 92, 93Overdispersion of adverse event report data, 760--762, 769in helminth infections, 251Overvaccination, 663, 701--702, 718, 728; *see also* RevaccinationOxytetracycline, 524, 540
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p150,95 integrin, 68Pan-American Health Organization, 659, 677Parasites, *see also* Helminthic vaccines economically important, 242overdispersion and, 251Parenteral vaccination, local immunity and, 475Parinaud\'s syndrome, 339Parturition, administering vaccines near, 74Parvodistemper vaccine, 5Parvovirus, Aleutian disease and, 558, 563; *see also* Canine parvovirus; Canine parvovirus type 2Parvovirus vaccines, 420, 421, 422, 426; *see also* Canine parvovirus vaccines; Canine parvovirus type 2 vaccinesPassive immunity, *see also* Maternal antibodies DNA immunization and, 171--172, 174immune stimulating complexes and, 410--411in poultry, 483pseudorabies vaccines and, 621Pasteur, Louis anthrax vaccines and, 11, 12, 13--14origin of vaccinology and, 8, 22rabies vaccine and, 311*Pasteurella canina*, 19; *see also* Canine distemper*Pasteurella haemolytica* vaccine, 689--690, 695*Pasteurella multocida, see* Atrophic rhinitisPasture contamination, in host-parasite relations, 249, 254Pasture management, in host-parasiterelations, 250Pathogens, resistance to, 42PauA plasminogen activator, 263--264PCR, *see* Polymerase chain reaction (PCR)Peptides antigastrointestinal, immune-induced anorexia and, 56--57synthetic, immune stimulation by, 183--184Periarteriolar lymphoid sheats, 408Periparturient immunosuppression, 71--72Peripheral blood lymphocytes, 441Peripheral blood mononuclear cells in cattle, CD45 T cell subpopulations, 276, 279, 280, 281γδ T cells in, 283in *Strongylus vulgaris* infections, 391, 400, 401Peripheral lymph node addressin complex, 63Periportal fibrosis, 398Peroxynitrite, 136Pertussis toxin, 84Pestiviruses, 207, 660Peyer\'s patches AgI/II adhesin and, 108cholera toxin, B subunit and, 110immune stimulating complexes and, 409interleukin-1 and, 94leukocyte trafficking and, 69--70in mucosal immune response, 435oral vaccines and, 105--106Pharmaceutical companies, *see* Vaccine industryPharmaceutical legislation, *see* Virus Serum Toxin Act*PHARMEUROPA*, 606Pheasants, 554*Phoca sibirca*, 552*Phoca vitulina*, 552Phocine distemper virus, 552Physalix vaccine, 19Pica, 554Pigs, *see* SwinePlague, 342Plasma cells, *see* Antibody-secreting cellsPlasmid immunization, *see* DNA immunizationPlasmids, *see* Virus vectorsPlasminogen activators, 263--264Platelet/endothelial cell adhesion molecule 1, 62, 69Platelets, CD62P adhesion molecule in, 66Pneumonia, equine, in foals, 372Poliomyelitis vaccine, 429--430, 684--685, 750Poliovirus, 429Polyarthritis, immune-mediated, 721Polyclonal restriction, in HIV infected Bcells, 120Polygenes, disease resistance and, 43--44Polyimmunoglobulin receptor, 434Polylactosamine-1 antigen, 128Polymerase chain reaction (PCR), *seealso* Reverse transcriptase-polymerase chain reactionin diagnostic assays, 26, 205, 231, 372Polyneuropathy, postvaccinal, 717Polysaccharides, bacterial, homology withHIV-1 envelope, 127--128Polyvalent vaccines, 5--6 advantages of, 467adverse vaccine reactions and, 718--719, 722, 724for bovine mastitis, 261bovine virus diarrhea virus vaccines in, 208for canine coronavirus, 301--302, 314for canine distemper, 294--295in DNA immunization, 174--175for fish, 547--549for kennel cough, 315, 316limitations of, 174overadministration of, 728safety and, 291in vaccine-induced autoimmunity experiments, 735--745virus vectors and, 148Ponies, *Strongylus vulgaris* infections and, 390--402Porcine group A rotaviruses, 433Porcine group A rotavirus vaccines, 440--442Porcine reproductive and respiratory syndrome, 458Porcine reproductive and respiratory syndrome vaccine, 421, 427Porcine respiratory coronavirus mucosal immune response to, 436--439pathogenesis of, 431--433Porcine respiratory coronavirus vaccines, 433--434Positive feedback loop, in host-parasiterelations, 249--250Postcapillary venules, 61--62, 65Postmarketing surveillance, 706--709, 710 bias and, 753, 755--757concepts of causality and, 754--755data collection in, 751--753difficulties in interpreting, 757--758implications for public policy, 750--751objectives of, 750--751, 757Post-translational modification, virus vectors and, 148Postvaccinal encephalitis, 294--295, 296, 301--302, 312Postvaccinal polyneuropathy, 717Potassium bichromate, 14Potency testing, in licensing procedures, 589*Potos flavus*, 552Poultry effects of conjugated linoleic acid in, 56immune-induced wasting and, 54, 56--57immune system of, 487--490specific pathogen free, 504, 505, 507, 511, 612--613type C botulism and, 554Poultry industry, *see also In ovo* vaccination bacterial infections and, 511--512coccidiosis and, 512common infectious diseases of, 482--483commonly used vaccines in, 483, 490disease prevention in, 482--483, 490intensive rearing system in, 481--482output of, 481, 490recombinant vaccines in, 486--487vaccination programs in, 484--485vaccine costs in, 175virus vectors and, 148--149Poultry vaccines commonly used, 483, 490delivery methods in, 485, 490DNA, 520--521recombinant, 486--487, 519--521subunit, 519synthetic peptides and, 519--520in vaccination programs, 484--485virus vectors and, 518--519*Poxviridae*, 518Poxvirus vectors, 146, 150, 151, 153, 467--469Preclinical testing ecology of infection and, 29--31future of, 34--36genetic testing and, 32methods in, 31--32overview of, 26predictive value of, 33--34Pregnancy suppression of cell-mediated immune response and, 71--72vaccination and, 74, 718Premunition, 117Prepuce, bovine trichomoniasis and, 230Preventive medicine genetic testing and, 32preclinical testing and, 33--34Primucell vaccine, 351--355Probability, adverse event reports and, 757, 769*Procyon lator*, 553Professional organizations, in veterinarystandardization, 658--659Proinflammatory cytokines, excessive induction of, 687--688Promoters, in recombinant virus vectors, 471Prostaglandin E*2*, 55Protective antigens, helminthic vaccines and, 242--245Protective immunity, *see also* Acquired immunity; Active immunity cell-mediated immune response and, 524DNA vaccines and, 171*Edwardsiella ictaluri* RE-33 vaccine and, 531--531, 534--535 enteric septicemia of catfish and, 525immune stimulating complexes and, 411pseudorabies vaccines and, 452--455, 457time to develop, 692Protein assays, *see also* Acute phase protein assays human, international standardization in, 651--652Proteins, *see* Acute phase proteinsProteinuria, 743P-selectin glycoprotein ligand, 62Pseudocapsular proteins, 260*Pseudomonas aeruginosa* vaccine, 423Pseudorabies vaccines, 421 European Union licensing procedures for, 615--625immunes responses to, 447--448, 451--452interluekin 12 and, 455--456, 458protective immunity and, 452--455, 457recombinant, 469, 573residual virulence and, 687Pseudorabies virus attenuated, 457Aujeszky\'s disease and, 451distribution, 659economic costs of, 464gamma interferon and, 454glycoproteins, in swinepox recombinant vaccine, 474immune response to, 457mortality rates, 464Psittacosis, 31Public health *Bartonella henselae* and, 340, 342leptospirosis and, 318*Toxoplasma gondii* and, 338, 342zoonotic pathogens and, 334, 335, 342Public policy, vaccination risk-benefit analysis and, 750--751Puntoni, V., 21, 22Pups canine distemper vaccines and, 294, 295canine parvovirus type 2 vaccines and, 297--298, 299--300timing of vaccination and, 661, 663Pustular vulvovaginitis, 197Pyrexia, 395, 398, 399
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QTL, *see* Quantitative trait lociQuantitative trait loci (QTL), disease resistance and, 40, 42, 43--44Quasi-likelihood methods, adverse event report data and, 762, 768--769Quil A, in helminthic vaccines, 246, 247*Quillaja saponaria*, 405, 406
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Rabies ecology of, 29equine, 367human mortality and, 571--572immune stimulating complexes and, 408, 409overview of, 311preclinical detection and, 26transmission to humans, 335viral glycoprotein in Raboral V-RG vaccine, 574wild reservoirs of, 29, 34, 572Rabies vaccines, *see also* Raboral V-RG vaccine feline, risk management for, 709recombinant, 475residual virulence and, 686, 687in vaccine-induced autoimmunity experiments, 735--745vaccinia virus vector, 153Raboral V-RG vaccine construction of, 574controlling coyote and gray fox rabies with, 580--581controlling raccoon rabies with, 573, 576--580development of, 572--573mechanism of action in, 574--575oral administration and, 572, 582success of, 582USDA testing of, 575--576Raccoonpox virus, 475Raccoons polyvalent vaccines and, 553rabies control in, 573, 576--580Rainbow trout furunculosis and, 525*Vibrio viscosus* and, 546--547Ratites, 481Reactivation experiments, bovine herpesvirus 1 vaccines and, 203--204C-Reactive protein, 646, 650Recombinant DNA technology, *see* Biotechnology; DNA immunizationRecombinant vaccines, *see also* Virus vectors antigen production and, 467biotechnology and, 521--522, 581--582canine, 292for canine distemper, 296, 310, 312for feline immunodeficiency virus, 328--329foreign hosts and, 476future of, 522immune responses and, 475licensing procedures for, 590multivalency and, 476for poultry, 486--487for rabies, 311, 572--573for transmissible gastroenteritis virus, 440for tuberculosis, 139USDA classification of, 573--574virus-like particles and, 442Recombination, homologous DNA integration and, 173in recombinant vaccine formation, 471, 518, 574reversion to virulence and, 475Red pandas, 552Reference reagents, international standards, 676--677Registration, *see* Licensing procedures (European Union); Licensing procedures (United States)Regulatory agencies, *see also* Animal and Plant Health Inspection Service; Center for Veterinary Biologics; European Pharmacopoeia; Office Inter-Regulatory national des Epizooties; U.S. Department of AgricultureDNA immunization and, 172--173vaccine label information and, 634Relative percent survival defined, 527, 542*Edwardsiella ictaluri* RE-33 vaccine and, 531--532, 534Renal amyloidosis, inherited, 721Renal failure leptospirosis and, 317Lyme disease and, 317vaccine-induced, 717Reoviridae, 365Reovirus, human, 510Respiratory disease, *see also* Porcine reproductive and respiratory syndrome; Porcine respiratory coronavirus; Respiratory syncytial virus avian, 482bovine, 207--208, *see also* Bovine respiratory syncytial virusequine rhinopneumonitis, 361--363feline, 3in swine, economic costs of, 464Respiratory syncytial virus, *see also* Bovine respiratory syncytial virus human, 187immune stimulating complexes and, 410vaccines, enhanced disease and, 188Respiratory tract immunization, bovine trichomoniasis and, 229Retroviruses, 366 immune stimulating complexes and, 411oncogenes and, 32Revaccination, *see also* Annual vaccinations; Overvaccination adverse reactions and, 718canine vaccines and, 303, 318frequency of, 663, 725--727mink distemper vaccine and, 560vaccine label statements on, 639Reverse transcriptase-polymerase chain reaction, in diagnostics, 209, 361, 372Reversion*Edwardsiella ictaluri* RE-33 vaccine and, 529 in pseudorabies vaccines, testing for, 618risks of, 466via homologous recombination, 475Rhabdoviridae, 367, 371Rhesus macaques, HIV-1/SIV protection in, 411Rheumatoid arthritis, 706, 742, 743Rhinopneumonitis virus, *see* Equine rhinopneumonitis virusRhinotracheitis, *see* Infectious bovine rhinotracheitisRhinovirus type 2, 127*Rhodococcus equi*, 372Rickettsiosis ecology of infection and, 29, 31preclinical detection and, 26Rifampicin, 527, 532Rinderpest, 669--670Risk assessment postmarketing surveillance and, 706--709, 710public *vs.* private, 750--751sources of data on, 704--706steps in, 702--703Risk communication, 709--710Risk difference, 751Risk factor epidemiology, 755Risk management, 709RNA viruses mutation in, 2--3synthetic peptide-stimulated immunity and, 184as virus vectors, 147Rockborn canine distemper vaccine strain, 293--294, 295, 296, 312*Rodococcus equi*, 411Romet, 540Rotaviruses, 277--278 diarrhea and, 430equine, 367pathogenesis of, 429, 433Rotavirus vaccines, 421, 427, 433, 440--442Rottweilers, 661Roux, Emil, 13, 14Ruminants, *see also* Cattle immunization development and, 285
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Safety, *see* Vaccine safety; Vaccine safety testingSaliva-binding region, 106Salmon, *Vibrio viscosus* and, 544, 546--547*Salmonella cholerasuis* vaccine, 421, 427*Salmonella dublin*, 96*Salmonella* spp. ecology of, 29, 31equine infections and, 371poultry infections and, 512zoonotic infections and, 342*Salmonella typhimurium*, preclinical detection and, 26Salmonella vaccines*in ovo* vaccination and, 512Re-17, for clinical coliform mastitis, 265, 269 for swine, 421, 427Salmonella vectors for mucosal vaccines, 106, 108--109, 111for SBR-CTA2/B chimeric cholera toxin, 106, 108--109for transmissible gastroenteritis virus vaccine, 440Salmonids, antibiotics and, 543Sanitary and Phytosanitary Agreement(World Trade Organization), 677, 678Saponins, 169, 405, 406SBR-CTA2/B (chimeric cholera toxin protein), 106--109Seal morbillivirus, 410Secondary immune response, *see also* Anamnestic recall response; Immunologic memoryHIV-1 infection and, 127 in mucosal immune system, 111tuberculosis and, 136virus--antibody complexes and, 510Seed stock, *see* Master seeds; Vaccine seed stockSeizures, vaccine-induced, 717Selectins, in leukocyte trafficking, 62, 63, 65--67Self-selection, of adverse event report data, 756Sendai virus, 411Septicemia, *see also* Enteric septicemia of catfishbovine genital tract infections and, 218*Haemophilus somnus* infection and, 219Serengeti lions, 553Serials defined, 750prelicensing, 589--590Serum amyloid A, 644, 646Serum antibody titers, using to determine revaccination, 727Serum neutralization titer, protective levels of, 726--727Sexually transmitted disease bovine genital tract infections and, 218, 233campylobacteriosis and, 222contagious equine metritis and, 370systemic immunizations and, 223Shar Pei dogs, 721Shedding, *see* Nasal shedding; Oocyst shedding; Transmissibility; Virus sheddingSheep botulism and, 554*Toxoplasma gondii* and, 337Sheepdogs, *see* Old English sheepdogsSiberian seals, 552Simian immunodeficiency virus, 411Simian virus 5, 315Simian virus 40, 685Simulation models design and use of, 247--248of *Haemonchus* vaccines, 251--253of vaccination in host-parasite populations, 248--250, 254Single radial diffusion test, equine influenza and, 381, 385, 603Single radial hemolysis test, equine influenza and, 361, 381, 386, 603Skeletal deformities, conjugated linoleic acid and, 56Small animal practice polyvalent preparations and, 5--6use of vaccines in, 290Smallpox, 9, 10"Snyder Hill" canine distemper vaccine strain, 293, 296Somatic cell counts, in bovine mastitis diagnosis, 267, 269Specific pathogen free poultry, *see* Poultry, specific pathogen freeSpleen, virus--antibody complexes and, 511*Sporothrix schenckii*, 342Spotted hyenas, 553Stability testing, 632Stallions, contagious equine metritis and, 370Standards Commission (Office International des Epizooties), 670, 672--677, 678Staph A antigen, 128*Staphylococcus aureus* vaccines, 258--262, 268Sterile immunity, DNA vaccines and, 171Strangles, 369--370*Streptococcus agalactiae* vaccines, 261, 262*Streptococcus dysgalactiae*, 262--263*Streptococcus equi*, 369--370*Streptococcus equismilis* vaccines, 423, 427*Streptococcus suis* vaccines, 421, 423, 427*Streptococcus uberis* vaccines, 261, 263--264, 268, 269Stress effects on immunity, 70--74effects on leukocyte trafficking, 63--64*Strongylus vulgaris* control of, 390eosinophilia and, 390--391, 396equine, immune response to, 390--402pathogenesis, 390"Subclincal infections," 31Sublicensing, 592Substance P, 96Subunit vaccines biasing T cell responses and, 186cytokine adjuvants and, 457--458for feline immunodeficiency virus, 328--329importance of, 457for poultry, 519risks of reversion and, 466tuberculosis and, 139--140USDA classification of, 573Sudden infant death syndrome, 759*Suipoxvirus*, 469Surface proteins, in *Staphylococcus aureus* vaccines, 261Surveillance postmarketing, *see* Postmarketing surveillancein vaccine risk assessment, 704--706, 710Swine acute phase proteins and, 646--647cholera toxin adjuvanticity in, 86--92enteropathogenic viruses andenteric vaccines, 433--434group A rotavirus vaccines, 440--442mucosal immune response, 434--442pathogenesis of, 430--433transmissible gastroenteritis virus vaccines, 439--440feral, disease transmission and, 464immune-response selected, 43--49infectious diseases of, 463--467, 469neonates diarrheal disease and, 464--465swinepox virus and, 475--476pseudorabies virus and, 451pseudorabies virus vaccines and, 447--448, 451--452, 454, 455--456, 457, 458respiratory infections and, economic costs, 464*Toxoplasma gondii* and, 337Swine fever, 661--662Swine fever vaccine, 469Swine industry infectious diseases and, 463--465protein output of, 463Swinepox vaccine, 474--476, 477Swinepox virus, 469--470, 475--476Swinepox virus vector, 470--473Swine vaccines, overview of, 419--427Synthetic peptides immune stimulation by, 183--184poultry vaccines and, 519--520Systemic lupus erythematosus, 706, 742, 743
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T-263 vaccine, 337--338*Taxidea taxus*, 552*Taylorella equigenitalis*, 370T cell clones, DNA tuberculosis vaccines and, 140T cell immunodeficiency, 452T cell receptors activation of γδ T cells and, 283antigen recognition and, 182, 183in avian immune system, 489T cells, *see also* Cytotoxic T cell immune response antigen presenting cells and, 275--276antigen recognition and, 182--184antigens recognized by, identificationof, 186--187in avian immune system, 487, 488, 489, 490in cattle bovine respiratory syncytial virus immunity, 188--191, 192dendritic cell-induced responses and, 284--285identification of subpopulations in, 276, 278--282*in vivo* roles of, 276--278cholera toxin and, 93in deceptive imprinting, 119dual-signal integration and, 93--94immune stimulating complexes and, 408--409in mucosal adjuvanticity, 98--99in mucosal immune response, 434, 435response determining mechanisms and, 186SBR-CTA2/B chimeric cholera toxin protein and, 108suppression of polyclonal response in, 122trafficking and, 63, 64, 69in tuberculosis immunity, 136, 137workshop cluster numbers and, 276T cells, CD4, *see also* Th1 immune response; Th2 immune response antigen processing and, 184--185in avian immune system, 489in cattleafferent lymph veiled cells and, 284--285bovine respiratory syncytial virusimmunity, 188--190, 192bovine virus diarrhea virus and, 277identification of, 276identifying CD45 subpopulations in, 278--282*in vivo* roles of, 277 cytokine profiles of, 185--186interleukin 12 and, 450response determining mechanisms and, 186in tuberculosis immunity, 136, 138T cells, CD8 antigen processing and, 184--185antigens recognized by, identification of, 186--187in avian immune system, 489in cattleafferent lymph veiled cells and, 284--285bovine respiratory syncytial virusimmunity, 188, 189identification of, 276identifying CD45 subpopulations in, 278--282respiratory syncytial virus and, 277*in vivo* roles of, 277--278 response determining mechanisms and, 186T cells, γδ in cattleactivation and function of, 282--284bovine respiratory syncytial virusimmunity, 188identification of, 276trafficking of, 64glucocorticoids and, 73T cells, memory, *see also* Memory lymphocytesCD45 antigen and, 279, 280, 281--282 immune stimulating complexes and, 407*Teladorsagia circumcincta*, 242, 243Tetanus toxoid, 73, 93Tetra methyl benzidine, 648Texas, controlling wild animal rabies in, 580--581Th1 immune response characteristics of, 185--186defined, 42in DNA immunization, 167in hypersensitive reactions, 689immune stimulating complexes and, 410inhibition by interleukin 10, 401in tuberculosis immunity, 137Th2 immune response characteristics of, 185--186cholera toxin induction of, 93defined, 42in DNA immunization, 167helminthic infections and, 246, 391in hypersensitive reactions, 689immune stimulating complexes and, 410*Strongylus vulgaris* infections and, 401*Theileria parva*, 183Thimerosol, 685Thrombocytopenia, *see* Immune-mediated thrombocytopeniaThromboembolic disease, *Strongylus vulgaris* infections and, 390Thromboembolic meningoencephalitis, 686"Thuga," 305Thymidine kinase gene, 150 in fowlpox virus vector, 518in recombinant virus vectors, 471, 473in swinepox virus, 471Thymus-dependent antigens, 122--123Thymus gland, in avian immune system, 487, 488Thymus-independent antigens, 122--123Thyroglobulin autoantibodies, 720--721Thyroid disease, vaccine-induced, 720--721Thyroiditis, autoimmune, 723, 742Tick-borne diseases, 316, 360, 662Togaviridae, 364Toussaint, Henri, 8, 12, 13, 14, 22Toxoplasma encephalitis, 336*Toxoplasma gondii*, 335, 336--338, 342Trade, *see* International tradeTranscriptional regulation, glucocorticoids and, 73Transmissibility, *see also* Virus shedding of bovine herpesvirus 1 vaccines, 203of pseudorabies vaccine strains, 619Transmissible gastroenteritis vaccines, 420, 421, 423, 427, 433--434, 439--440Transmissible gastroenteritis virus, 349 attenuated, 431--434, 439mode of release in, 431mucosal immune response to, 436--439pathogenesis, 429, 431--433, 465in swine, economic costs of, 465Transmission, *see* Disease transmissionTransplacental immunization, 564Transporter for antigen presentation, 184Trichomoniasis, *see Tritrichomonas foetus*Trichostrongylid nematodes, 242; *see also* Helminthic vaccines aminopeptidases in, 245host immunity and, 250--251modeling of vaccines for, 251--253overdispersion and, 251*Trichuris muris*, 186, 401*Tritrichomonas foetus*, 224--232 diagnosis of, 231--232evasion of immune response by, 231genital mucosal inductive sites and, 228--230immune response to, 226--228, 230pathogenesis of, 224prevalence of, 224--225protective antigens of, 225--226vaccine development and, 233Trout, *see* Rainbow troutTrovac-NDV, 519*Trypanosoma congolense*, 278Tuberculosis acquired cell-mediated immunity and, 137--138γδ T cells and, 284human mortality and, 135, 141memory immunity and, 136preclinical detection and, 33--34process of infection in, 136--137Tuberculosis vaccines, 135, 136, 138--141Tumor necrosis factor acute phase proteins and, 645adjuvanticity in DNA immunization, 168excessive induction of by vaccines, 687tuberculosis and, 138Turkey herpesvirus, in Marek\'s disease vaccine, 496, 497, 498, 500, 502--503, 519Turkey herpesvirus vectors, 486, 519Turkeys, *see also* Poultry industry recombinant vaccines and, 486Turpentine injection, 646, 647Type III response, in hypersensitive reactions, 689--690Typing systems, in bovine mastitis diagnostics, 268

U {#cesec50e}
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Uasin Gishu pox, 11Ulcers, *Helicobacter pylori* and, 341Unconventional antigens, 121Underdeveloped countries, rabies in, 571--572United States controlling wildlife rabies in, 576--581licensing procedures infor modified live pseudorabies vaccine, 628--632for veterinary biological products, 586--593Virus Serum Toxin Act and, 585--586, 627 regulation of veterinary vaccines in, 682--684swine vaccine use in, 422, 423, 425, 426, 427wildlife reservoir species of rabies in, 572United States Pharmacopeia, 753United States Veterinary Biologics Establishment License, 587--588Unvaccinated animals, *see* Nonvaccinated animalsUremia, 317*Urocyn cineieoargenteus*, 552U.S. Department of Agriculture, *see also* Animal and Plant Health Inspection Service; Center for Veterinary Biologics; Licensing procedures (United States) adverse event report data and, 771annual revaccination regulations, 639classification of recombinant vaccines, 573--574collection of adverse event reports and, 753efficacy testing regulations, 635--637equine influenza vaccines and, 386licensure exemptions and, 592regulation of veterinary vaccines, 682--684safety testing regulations, 638testing of Raboral V-RG vaccine, 573, 575--576vaccine label information and, 634--641Veterinary Biologics program and, 586--587Uterus bovine campylobacteriosis and, 222--223bovine trichomoniasis and, 228--230

V {#cesec50f}
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Vaccination, *see also* Annual vaccination; DNA immunization; *In ovo* vaccination; Nonvaccinated animals; Revaccination adverse reactions and, *see* Adverse reactionsbenefits of, 663--665conventional, alternatives to, 716, 727--729cross-species, 551--555in disease prevention, 465--466economics of, 1--2, 661emerging infectious agents and, 2--3, 333, 334--335epidemiology and, 415--417, 666genetic predispositin and, 39--49of geriatric animals, 6, 725--726, 728goal of eradication in, 474holistic perspective and, 290--291immune-induced wasting and, 53, 54, 57of neonates, 297--298, 299--300, 661, 663, 694, 719origins of, 7--8overuse of, 663, 701--702, 718, 728overview of, 668of pregnant animals, 74, 718professional knowledge of, 2purpose of, 136reemerging infectious agents and, 333risks and, 662--665, 702--792standardization and, 658--662success of, 1Vaccine Adverse Event Reporting System, 753Vaccine delivery DNA immunization and, 165--166, 169--171intradermal, 165--166intragastric, 106, 109, 110intramuscular, 165, 170intranasal, 106, 109, 110, 310intraperitoneal, 440, 541--542, 549*in ovo*, 485, 490Vaccine development advances in immunology and, 182--187antigen processing and, 184--185antigen recognition and, 182--184biotechnology and, 182, 517, 521--522, 581--582, 665for bovine genital tract infections, 233for bovine respiratory syncytial virus, 192current trends in, 182deceptive imprinting and, 129epitope masking and, 130for equine diseases, 373for foot-and-mouth disease virus, 199future of, 665--666in helminthic vaccines, 242--254identification of T cell-recognized antigens and, 186--187for lentiviruses, 366in poultry vaccines, 486--487recombinant vaccines and, 467synthetic peptides and, 183--184T cell response pathways and, 185--186traditional approaches to, 181--182, 466virus vectors and, 146, 475Vaccine effectiveness, distinguished from vaccine efficacy, 751Vaccine efficacy distinguished from vaccine effectiveness, 751exposure of adverse effects and, 703interpreting, 3--4public concern with, 290quantitative definition of, 751U.S. regulations on, 684Vaccine efficacy testing of bovine herpesvirus 1 vaccines, 202--204of bovine virus diarrhea virus vaccines, 208of canine coronavirus vaccines, 301, 302of canine parvovirus type 2 vaccines, 298--300of canine vaccines, 291--292, 293codified, 635of conventional vaccines, 466disease prevention and, 416--417of enteric vaccines, 433of equine influenza vaccines, 380of feline infectious peritonitis vaccines, 354--355of fish vaccines, 542of foot-and-mouth disease vaccines, 199--200in licensing procedures, 589noncodified, 635--636of *in ovo* vaccination, 498--499of pseudorabies vaccines, 620--623, 629of Raboral V-RG vaccine, 575--576reported on vaccine labels, 635--637of swine vaccines, 420, 421, 423, 425USDA regulations, 635--637Vaccine industry, *see also* Licensing loyalty of veterinarians to, 3postmarketing surveillance and, 706--709recommendations for, 6research and development in, 3Vaccine labeling animal age information on, 639--640annual revaccination information on, 639directions for clinical use on, 638--639efficacy information on, 635--637, 684expectations for, 634improving standardization in, 640--641indications information on, 637information on multiple syndromes, 640in pseudorabies vaccine licensing, 632safety information on, 637--638, 684standardization of, 658veterinarian needs and, 633, 634Vaccine marketing, misuse of adverse event report data in, 771--772Vaccine production lots, *see* SerialsVaccines, *see also specific types;* Veterinary biological products administering concurrently, dangers of, 691, 693, 695administering near parturition, 74, 718adverse reactions to, *see* Adverse reactionsclinical use, directions for, 638--639contamination of, 684--685, 717--718conventional, overview of, 465--467costs of, 175cross-reactivity and, 743, 745failures, causes of, 129--130, 146, 595, 691--695holistic perspective and, 290--291human vaccine models and, 659hypersensitivity reactions and, 688--690immunogenic qualities of, 456--457improper handling of, 692licensing and registration of, *see* Licensing proceduresloyalty of veterinarians to, 3need for improvement in, 145--146partnership model for, 667risk assessment for, 702--703strategies for use, 666success of, 657--658, 682target species and, 660Vaccine safety, 710 characteristics of, 703frequency of administration and, 701--702problems in, 662--663U.S. regulations on, 683--684Vaccine safety testing of bovine herpesvirus 1 vaccines, 204--205of bovine virus diarrhea virus vaccines, 208--209of canine coronavirus vaccines, 301--302of canine parvovirus type 2 vaccines, 300of canine vaccines, 291of *Edwardsiella ictaluri* RE-33 vaccine, 528--529, 534of foot-and-mouth disease vaccines, 200in licensing procedures, 588--589of modified live virus vaccines, 466of nonimmunizing mutant viral vaccines, 293of Pseudorabies vaccines, 616--620, 629, 630--632public concern with, 290reported on vaccine labels, 637--638Vaccine seed stock, *see also* Master seeds canine parvovirus type 2 vaccines and, 298Vaccinia, 8, 9--11, 22Vaccinia virus vector, 146, 147, 153, 467--469, 475, 572, 574Vaccinology adjuvants and, 4--5DNA injections and, 4early anthrax vaccines, 11--17early discoveries in, 9--11origins of, 7--8polyvalent vaccines and, 5--6professional knowledge of, 2recommendations for, 6William Greenfield on, 15--16, 17Vaccinosis, 290, 715Vaculitis, 219Vagina bovine campylobacteriosis and, 222--223bovine trichomoniasis and, 228--230Valgus deformity, 56Vanguard-5 CV/L vaccine, 735*Varicellovirus*, 201; *see also* Bovine herpesvirus 1Varus deformity, 56Vascular cell adhesion molecule 1, 63Vectors, *see* Bacterial vectors; Virus vectorsVectorVax FP-N, 519Venereal campylobacteriosis, *see* CampylobacteriosisVenezuelan equine encephalitis, 364Venezuelan equine encephalitis vaccine, 685Venules, leukocyte trafficking and, 61--62, 65Verminous arteritis, 390, 398Vesicular stomatitis, 371Veterinarians animal welfare and, 664--665attitudes towards vaccines, 3in postmarketing surveillance of vaccines, 707risk communication and, 709--710risk management and, 709swine vaccines and, 420, 425, 427vaccine labels and, 633, 634Veterinary biological establishments, licensing of, 587--588Veterinary biological products defined, 586licensing ofEuropean Union, 595--607United States, 587--593, 627 new European definitions of, 598--600Virus Serum Toxin Act and, 585--586Veterinary Biologics program, 586--593Veterinary diagnostics, *see* Diagnostic medicineVeterinary laboratories, as OIE reference laboratories, 675--676Veterinary medicinal products, *see* Veterinary biological productsVeterinary microbiology, 6Veterinary practices corporate, postmarketing surveillance of vaccines and, 708standardization and, 658--659Veterinary Services, 627VetSmart, 708VH genes, in deceptive imprinting, 120--121*Vibrio anguillarum*, 548--549*Vibrio cholerae, see* Cholera toxin*Vibrio salmonicida*, 547, 548--549*Vibrio viscosus*, 544, 546--547*Vibrio wodanis*, 546Vibrosis, 547, 548; *see also* CampylobacteriosisViral diarrhea, enterpathogenic viruses and, 430Viral envelope deceptive imprinting and, 118HIV-1, similarity with other viruses, 127immune stimulating complexes and, 406, 410Viral envelope glycoprotein in feline immunodeficiency virus vaccines, 326, 328in recombinant swinepox vaccines, 474Viral neutralizing factor technology, 506--511Viremia bovine virus diarrhea virus and, 277in poultry, rispens-type vaccines and, 502--503Virulence, *see also* Reversion of *Haemophilus somnus*, 220modified live vaccines and, 466residual, in modified live vaccines, 686--687Virus-antibody complex vaccines, *in ovo* vaccination and, 506--511Viruses, *see also specific diseases;* Virus vectorsmutation in, 2--3"new," 2 replication limited, 150--151strain variability, effects on vaccination, 660Virus-like particle vaccines, 442Virus Serum Toxin Act (United States), 585--586, 627, 634, 683Virus shedding, *see also* Nasal shedding; Oocyst shedding; Transmissibility disease transmission and, 277, 464in pseudorabies vaccines, 618--619, 622Virus vectors, *see also* Recombinant vaccines; *specific vectors* advantages of, 148--149antigen production and, 467construction of, 147--148, 518disadvantages of, 149features of, 148formation of, 470--473, 477future of, 153, 155homologous recombination and, 471, 518, 574live attenuation and, 149--151overview of, 476--477, 517--518for poultry vaccines, 518--519poxviruses as, 467--469replication limited, 150--151risks of DNA integration and, 173risks of virulent recombination and, 475swinepox virus as, 469--470in USDA type II recombinant vaccines, 574in vaccine development, 146veterinary use of, 145, 151--153Vogt-Koyanagi-Harada syndrome, 721
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Waldeyer\'s ring, 110Walking catfish, 525Waterfowl, type C botulism and, 554--555WB test, 124, 126WC1 antigen, 276, 282--284Weibel-Palade bodies, 66Weight, in assessing pseudorabies vaccine efficacy, 621--622Weimaraners, 723--725Western equine encephalitis, 364Whole inactivated vaccines, *see also* Inactivated vaccines for feline immunodeficiency virus, 326--327, 328Wild animals canine distemper virus and, 551--553*Clostridium botulinum* Type C and, 553--555as rabies reservoirs, 29, 34, 572rabies vaccination and, *see* Raboral V-RG vaccinevaccination and, 664Winter ulcer, 544, 546--547Workshop cluster numbers, 276World Health Organization, 677 on emerging strains of equine influenza, 381--382on equine influenza vaccines, 380--381European Pharmacopoeia and, 604International Association of Biological Standardization and, 610World Trade Organization, 677, 678
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Xanthine-guanine phosphoribosyltransferase gene, 471
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*Yersinia pestis*, 342*Yersinia ruckeri*, 540; *see also* Enteric redmouth disease
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Zoonotic disease *Bartonella henselae* and, 338--340cats and, 335--342controlling with vaccination, 664ecology of, 29, 31*Helicobacter pylori* and, 341leptospirosis and, 371--372*Microsporum canis* and, 342preclinical detection and, 26public health and, 334, 335, 342*Toxoplasma gondii* and, 336--338*Yersinia pestis* and, 342Zoos, type C botulism and, 555
